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Title: Outcomes of Children Transferring Out of Red Cross War Memorial Children’s Hospital 
HIV Cohort using Linkage to the National Health Laboratory Service Data. 
Background and Rationale 
Paediatric antiretroviral (ART) care in the Western Cape Province (WCP) has evolved 
following South Africa’s (SA) massive roll-out of antiretroviral therapy in 2004 in response to 
the country’s human immunodeficiency virus (HIV) epidemic. Decentralization of paediatric 
ART services was adopted in scaling up access to ART services for children living with HIV.  
Although children now mainly initiate ART at lower level facilities, sick or very young infants 
continue to initiate ART at tertiary health facilities and become eligible for transfer to lower 
level facilities after stabilization at tertiary health facilities. There has been limited assessment 
of the effectiveness of this model of ART care since its implementation. 
Aims and Objectives 
The primary objective of this study is to determine the proportion of children that successfully 
transferred from Red Cross War Memorial Children’s Hospital (RCWMCH) to referral 
facilities for continued ART within 18 or 48 months of their last appointment at RCWMCH. 
Successful transfer was defined in two ways: a laboratory test performed by a lower level 
facility (i) ≤18 months or (ii) ≤48 months after transfer date. The first interval corresponds to 
guideline recommendations for annual CD4/viral load monitoring; the second captures all 
children retained in care. 
Our secondary objectives are as follows: 
1. To identify the determinants of successful transfer from RCWMCH.
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2. To describe the CD4 and viral load outcomes of children that successfully transferred 
to referral lower health facilities within WCP.  
3. To determine the feasibility of using the SA National Health Laboratory Service 
(NHLS) data for routine monitoring of children transferring between paediatric ART 
sites. 
Methods 
A retrospective analysis was performed. The study population was children below the age of 
16 years who were initiated onto ART at RCWMCH and transferred out to lower level facilities 
within the WCP from December 31, 2007 - January 1, 2012. We described children’s 
characteristics before transfer out and post-transfer date. In those who successfully transferred, 
we compared their immunological and virological status at transfer out and at the first visit 
within 48 months after the transfer out date, using median change for continuous variables and 
difference in proportions for categorical variables.  
Results  
Data from 1127 children with median age of 5.6 months (interquartile range [IQR] 3.1-19.9) 
was included; at ART initiation 85% had WHO stage III/IV disease and 57% were severely 
immunosuppressed. A total of 725 (64%) children were transferred; 69% (496) and 76% (541) 
successfully transferred within 18 and 48 months respectively. Since there is about 90% 
compliance with annual CD4/viral load monitoring guidelines, we estimate that up to 85% of 
children may have actually successfully transferred. Median time to successful transfer was 5.4 
months (IQR 3.7-7.8). Among the 184 children (25%) who did not transfer successfully, 11% 
returned to RCWMCH. In patients who successfully transferred, median (IQR) CD4% 
increased between transfer out and first visit post-transfer [25.1% (17.3-33.8%) vs 30.2% 
(22.9-36.6%), p-value = 0.0000]. Children who had their transfer sites recorded in the database 
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and those transferred before 2010 were identified to be associated with successful transfer 
(adjusted odds ratio (aOR 7.99, 95% Confidence Interval (CI) (2.3-28.5 and aOR 5.21, 95% 
CI 1.5-18.4 respectively). 
Conclusion  
The proportion of children remaining in HIV care by 48 months after transfer out was at least 
76% and 92% of those that transferred successfully reached the referral facility and undergoing 
a laboratory test within 18 months of transfer out. In children who successfully transferred, 
CD4% and viral load suppression improved after transfer. This suggests that paediatric ART 
decentralization is feasible with good outcomes. However, outcomes in those who were lost 
after transfer out need further investigation. 
Part A: Is the study protocol as submitted for Departmental and Ethical Approval is presented 
here.   
Part B: A structured literature review of observational studies conducted in low and middle 
income countries on the outcomes of patients in decentralized models of ART care is presented. 
Part C:  A journal-ready manuscript according to the requirements of the South African 
Medical Journal (author’s information included as Appendix E) is presented.   
Appendices: Includes all additional documents necessary as addendums in the presentation of 
this dissertation. 
The Vancouver referencing style has been used for Part A and B of this mini-dissertation 
however, in keeping with the instructions for authors as specified by the South African Medical 
Journal Part C: The Journal Ready Manuscript includes references in the style recommended 
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PART A: PROTOCOL 
1 
1 Introduction 
1.1 Burden of Pediatric HIV and Poor Access to Treatment 
Sub-Saharan Africa remains the epicentre of the epidemic of human immunodeficiency 
syndrome (HIV), accounting for approximately 91% of the world's total number of children 
<16 years living with HIV (1). Between the year 2011 and 2012, globally 11% of children 
eligible for antiretroviral therapy (ART) were receiving it compared to 21% in adults (2). 
During this period, 360,000 South Africa (SA) children were living with HIV and about 16,000 
children were newly infected with HIV (1). In the absence of treatment, about half of the 
children living with HIV will die before their second birthday (3, 4).  Despite rapid expansion 
of ART access in resource-limited settings, infants and children continue to start ART late 
when their prognosis is sub-optimal (5, 6). In 2010, >60% of children initiated ART with severe 
immune suppression or with World Health Organization (WHO) Stage 3 or 4 disease across 
Southern African countries, both factors are associated with a poor prognosis (7). 
The access of children to ART early in their disease has been described as important for an 
effective paediatric HIV/AIDS programme in resource-limited settings (8). The gap between 
adult’s and children’s access to ART services in resource-limited settings is partly due to rapid 
progression of HIV disease in children and poor access to early infant diagnosis testing. Other 
barriers include complex guidelines and treatment schedules for children and lack of staff who 
are skilled and confident in paediatric HIV care (9). In addition, there may be fewer facilities 
offering paediatric ART with long distances between the health facility and the patient’s home 
(9-11). These barriers mean that children with HIV frequently present for care when their 
disease is advanced. Therefore, expansion of ART programmes to increase children’s access 




1.2 Decentralization as a Solution 
Decentralization of paediatric ART care is a way of addressing the challenges of paediatric 
HIV care and treatment in resource-limited settings. This model of care had been previously 
adopted for scaling up access to ART services in adults (12). Decentralization of ART services 
aims to improve the outcomes of patients in resource-limited settings where there are frequently 
limited human resources and weak health systems (13).  
Recently, this model has demonstrated promising results for scaling up ART services in 
resource-limited settings (14, 15). Even though models of decentralization differ across 
different settings, the shift of services from a centralized site to lower level health facilities 
forms the basic component of all models of decentralization (16). The lower level health 
facilities are not only closer to patient’s home, but also help in decongesting the number of 
patients receiving ART at specialized central hospitals (16). This model of care may also 
include task shifting or the devolution of specific tasks from highly qualified health workers to 
less qualified health workers paving the way for better utilization of highly skilled health 
workers at centralized hospitals to manage the sickest children with poor clinical and 
immunological status, including children with comorbidities (10, 17). Although, task shifting 
and decentralization are different approaches to improving patients access to care, in some 
settings such as SA they are synonymous since services at lower level health care facilities are 
often delivered by lower cadres of staff. Furthermore, changes have been made to ART service 
delivery in SA to accommodate the decentralization and task-shifting model of care for people 
living with HIV (18).  
In 2010, the government of SA revised its HIV treatment guidelines following the positive 
results of a pilot task-shifting intervention in routine care settings (19). These results, coupled 
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with the results of a SA randomized control trial, which reported similar treatment outcomes 
of patients who were initiated on ART by doctors but monitored by nurses at primary health 
care clinics  thereafter compared to those managed by doctors alone, supported programme 
changes in the SA 2010 treatment guidelines (18, 19). Consequently, the SA 2010 treatment 
guidelines allow nurses to initiate antiretroviral drugs for the treatment and prevention of HIV 
and also enable primary health care facilities to initiate, manage, monitor and refer patients 
(20).  
A recent systematic review on different models of decentralization in resource-limited settings 
suggests comparable outcomes in both adult and paediatric patients with HIV receiving ART 
services at decentralized health facilities compared to those receiving ART services at 
centralized health facilities. In addition, no significant differences in clinical and 
immunological outcomes were found irrespective of whether a less qualified health worker or 
a highly qualified health worker delivered the ART service (16). Consequently, 
decentralization of ART services through the primary health care system has been considered 
to be paramount for increasing patients access to HIV care and their retention in care as the 
HIV programme continue to expand in resource-limited settings (16, 17). 
1.3 Western Cape Pediatric ART Decentralization Model 
South Africa, with the largest paediatric ART programme in the world (21) commenced rapid 
scale-up of ART services in 2004 following the launch of the SA national ART programme in 
April 2004. The majority of children were treated at secondary level facilities and were initiated 
on ART based on SA immunological and clinical eligibility criteria for ART initiation. The SA 
ART eligibility criteria for children from 2004 - 2010 are summarized in table 1 below, since 




Table 1: SA ART Guidelines for Paediatric ART Management from 2004 – 2010 (7) 
Year 2004 – 2009  2010 onwards 
ART initiation criteria       WHO disease stage III/IV  




≤ 11 months: all 
< 18 months: CD4% <20 12 – 59 months: CD4 <750 
or 25% 
≥ 18 months: CD4% < 15 ≥ 5 years: CD4 < 350 
 
By the end of March 2006, thirty-seven public health facilities were accredited to manage 
children eligible for ART in the Western Cape Province (22). The accreditation of these public 
health facilities heralded the implementation of the decentralized delivery of paediatric ART 
services in Western Cape Province (22). 
The decentralization of paediatric HIV care in the Western Cape Province was introduced 
systematically. Patients stable on pills were the first group transferred out from the tertiary 
health facilities, followed by stable children on syrups. However, as capacities improved at the 
lower level facilities, these facilities began to initiate and monitor children on site. Very sick 
unstable infants and children continued to be initiated and stabilized on ART at the tertiary 
health facilities and were then transferred out after stabilization for continued ART care at 
lower level health facilities within the Western Cape Province (22, 23).   
In addition to transferring clinically stable children out of tertiary health care for the 
continuation of care at the lower level health facilities, tertiary health facilities have also 
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supported decentralization by contributing to building capacities of workers at lower level 
health facilities. Staff from tertiary facilities have provided mentoring and maintained regular 
communication with lower level health facilities. In addition, there were regular visits by the 
tertiary health care paediatricians to lower level health facilities as the number of children at 
the lower level health facilities increased.  
Early outcomes of the Western Cape Province paediatric decentralized ART model of HIV 
care suggested that this approach facilitated remarkable progress in delivering ART services to 
HIV-infected children. Between March 2004 - September 2006, the proportion of children 
receiving ART at the three tertiary hospitals in the province decreased from 78.4% - 38% (9). 
1.4 Red Cross War Memorial Children's Hospital Paediatric ART Decentralization 
Red Cross Memorial Children’s Hospital (RCWMCH) is a leading institution in advancing the 
care of HIV-infected children in the Western Cape Province and SA. The RCWMCH ART 
programme for children started at the beginning of 2002 prior to the national ART programme 
of 2004 by providing ART services for children and their HIV-infected parents. This 
programme was subsequently incorporated into the provincial decentralized network for the 
delivery HIV care, by the HIV/AIDS directorate of the Western Cape Department of Health in 
March 2004 (24, 25). The majority of children at RCWMCH requiring ART are children with 
advanced HIV infection (WHO stage 3 and 4). About 85% of these children start ART during 
a hospital admission, including 15-20% who start ART in the intensive care unit of the hospital 
(26).   
The RCWMCH 2011 operational guidelines for ART include ART initiation within two weeks 
of admission for all HIV-infected ART-naïve children <12 months of age and children with 
advanced disease. Stable HIV-infected children > 12 months of age who are eligible for ART 
can be referred to commence ART at the local community ART clinic unless the child requires 
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specialist services at RCWMCH. RCWMCH children are referred to community clinics for the 
continuation of ART and routine follow up where possible (26). Children who are referred to 
lower level facilities are provided with a referral sheet containing the name of the referral site, 
next appointment date at referral site, medical summary, most recent laboratory test results, 
and, if already on ART, the current drug regimen. This referral sheet should be given to the 
referral facility upon arrival for the continuation of HIV care (26). The routine laboratory 
monitoring of RCWMCH children includes CD4 absolute and percent as well as viral load. 
Although the recommended frequency of monitoring has changed over time, current National 
Department of Health guidelines are that these should be measured at initiation, after 6 months, 
after 1 year and annually thereafter (26).  
An early study on the provision of ART for children at RCWMCH reported that 409 children 
had enrolled on the ART programme at RCWMCH with a median age of 23 months 
(interquartile range (IQR): 8.9 - 54.6 months) by the end of December 2004. After a  year on 
ART 46/409 (11.2%) had been transferred out to another ART treatment site (lower level of 
health facilities) for the continuation of ART care (25). 
2 Support from Literature 
In the context of massive scale-up of HIV services in resource-limited settings, retention in 
care of patients infected with HIV is salient for optimal clinical outcomes in patients on ART 
(27). Although it is expected that a decentralized model of HIV care will help remove some 
barriers to HIV care in resource-limited settings, it is important to improve on the tracking 
system of patients transferring between HIV care sites to accurately assess retention at the level 
of the ART programme, and not just at a particular facility (28). The gaps in the methodological 
approach used to quantify retention of patients on ART in resource-limited settings have been 
well discussed (27). A 2014 systematic review of paediatric patients on HIV treatment in low 
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and middle-income countries between the year 2008 and 2013 reported that 85% of patients 
were retained in care at 12 months and 81% at both 24 and 36 months after ART initiation. 
However, when examining ART outcomes, this review excludes patients who were reported to 
have been transferred from treatment sites from both the numerator and the denominator since 
their outcomes are unknown after transfer out (29). Similarly, a study where patients were 
censored at the time of transfer reported an 86.9% and 82.4% retention in ART sites at 12 and 
36 months after ART initiation respectively. In addition, this study also reported that most 
transfers of patients occurred between 6 and 12 months after initiation onto ART (83.4%) (30). 
The interpretation of the above estimates of retention of patients on ART has been greeted with 
caution because these studies did not capture information either about patient`s referred by 
clinicians to lower level health facilities for continuation of HIV care or of silent transfers that 
occur between treatment sites. “Silent” transfers occur when patients themselves start to receive 
HIV care at a new treatment site without informing the previous treatment site that they will 
be transferring to a new facility for HIV care. Retention in care within a decentralized network 
of ART services could be underestimated if these retention estimates of patients on ART do 
not take into account patients that transfer care (27). Indeed, this gap in patients tracking 
systems hinders capacity to assess the retention outcome of patients in a decentralized model 
of ART services.  
As transfer patterns and outcomes may be dependent on the context, it is important to conduct 
local research to evaluate interventions such as the decentralized delivery of ART services. In 
particular, new methodological approaches are needed to strengthen evaluation of  the 
decentralized model of HIV care (27). To this end, a SA adult study shed light on the 
importance of evaluating the outcomes of patients transferred out in a decentralized ART care 
model. This study reported higher mortality in patients transferred out from ART sites 
compared to patients retained at ART initiation sites at three months after transfer date (31). 
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However, it is noteworthy that most studies assessing outcomes of patients on ART 
programmes censor transferred out patients. This explains the paucity of information on 
outcomes of patients moving from centralized ART sites (mostly higher level health facilities) 
to lower level health facilities and its impact on estimates of retention in care (14, 32, 33).  
3 Problem Identification 
The ongoing scale-up of paediatric ART services in SA and Western Cape Province is through 
a decentralized service with different levels of health care. Knowledge of a patient’s movement 
between facilities is, therefore, necessary for the evaluation of a patient’s outcomes in the 
context of this decentralized model of HIV care (34, 35). This knowledge is important since 
effective HIV treatment requires uninterrupted treatment and retention of patients on ART 
programmes (27). However, there is sparse information on children’s outcomes after transfer 
out from the treatment initiation site in resource-limited settings (10, 14, 27, 31).  
This problem leads to the question: ˝What are the outcomes of children transferring out of 
RCWMCH? ˮ and “What are the determinants of successful transfer in children transferred out 
from RCWMCH? ˮ.  
4 The Rationale for the Proposed Study 
The ongoing scale-up of ART services in SA has achieved tremendous results with more than 
2.7 million people taking antiretroviral drugs and improved access to services throughout the 
country (36). Yet, there are still challenges of patient adherence to treatment, long-term 
retention of children in a treatment programme and the continued engagement of HIV-infected 
children in care. These are all important in ensuring uninterrupted treatment of children on the 
treatment programme (32). Interruption of ART can reverse the health benefits of starting  ART 
and also cause drug resistance mutations in patients, limiting future treatment options (37).  
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Therefore, successful retention of children in treatment programmes such as the decentralized 
paediatric ART programme of Western Cape Province is essential to achieve the National 
Strategic Plan 2012-2016 goal 2, to keep 70% of patients alive and on treatment five years after 
ART initiation. This is also in line with the global goal to retain 90% of all people with 
diagnosed HIV infection on ART by 2020 (38, 39).  
Furthermore, a recent study on characteristics of patients transferring out of the ART service 
in SA has emphasized the importance of information tracking systems for patients transferring 
between ART sites, as the proportion of transferring patients are increasing due to the ongoing 
scale-up of ART services in SA (35). To the best of our knowledge, there are only two studies 
that published a sub-group analysis of outcomes of children transferred out from Tygerberg 
hospital and RCWMCH respectively. Both are Western Cape Province tertiary health facilities 
but neither of the two studies aimed to describe the overall proportion of patients successfully 
transferred from the tertiary facility or the predictors of successful transfer (40, 41). 
5 Study Objectives 
1. To estimate the proportion of children that successfully transferred to referral facilities 
providing continued ART services for children transferred out from RCWMCH within 
18 months of their last appointment at RCWMCH using linkage to the Provincial 
National Health Laboratory Service (NHLS) data. 
2. To describe CD4 and viral load outcomes of RCWMCH stabilized HIV-infected 
children that successfully transferred into referral sites. 
3. To identify and examine predictors of successful transfer. 
4. To determine the feasibility of using the SA NHLS data for routine monitoring children 




6.1 Study Design 
This will be a retrospective analysis of children initiated on ART at RCWMCH and transferred 
to lower level health facilities for continuation of HIV care from between December 31, 2007 
and January 1, 2012. Routine clinical follow-up data was collected for this cohort of children 
as part of standard treatment and monitoring of HIV and ART.  
6.2 Characteristics of Study Population and Red Cross War Memorial Children 
Hospital 
This study will include all HIV-infected children who were below the age of 16 years at ART 
initiation at RCWMCH and were transferred to another facility in the Western Cape Province 
to continue ART. RCWMCH is a SA tertiary health facility affiliated with the University of 
Cape Town (UCT). Children are referred to RCWMCH from all the nine Provinces of SA and 
all over Africa. The range of paediatric services offered at RCWMCH includes quaternary, 
tertiary, and secondary services. RCWMCH is also actively involved in paediatric outreach 
and support programmes across SA (42).  About 260 000 patients visit RCWMCH every year, 
the majority of these patients are from marginalized communities and are extremely poor. One-
third of children managed at RCWMCH are younger than a year (43).  
6.3 Data Collection and Variables 
Study data will come from patients who initiated ART at RCWMCH for the period from 
between December 31, 2007 and January 1, 2012 and transferred out during this period. All 
children’s data were collected using a standard datasheet form according to the 2011 
RCWMCH operational guideline for the management of HIV (26) and stored in a password 
protected access database kept on a password protected personal computer in a locked office. 
These patients’ information were extracted from the RCWMCH database and linked to 
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Western Cape Province laboratory data by Western Cape Department of Health staff. Patients’ 
follow-up outcomes can, therefore, be assessed using the linked data. The start of the study 
period in 2007 was chosen as the Western Cape implemented the use of a unique patient 
number in 2007, facilitating linkage of patient data across facilities. The end of the study period 
is at the end of 2011, as the linkage was conducted using data up to the end of 2012, and we 
wanted to ensure that there was at least a year of laboratory data available after the last patient 
was transferred out.  
We will include children’s laboratory information variables of CD4 counts/percentage and viral 
load from either the Western Cape NHLS Database or the RCWMCH database, in addition to 
demographic data, date of ART start and referral site of children who were transferred out 
extracted from the RCWMCH database. 
6.4 Sample size and Power Consideration 
The proportion of ART naïve children who remained in treatment clinics at 12 months on ART 
in the Western Cape Province, SA is estimated to be 0.87 (30, 44). We assume that transferring 
stabilized children to lower levels health facilities would neither increase nor decrease the rate 
of retention in their new health facilities. Thus, we hypothesized a difference of < 8% in 
retention rate. The table below provides a list of sample sizes that will be needed to detect a 
range of differences in retention at 0.05 alpha and 80% power. 
Table 2: List of Sample Sizes Needed to Detect a Range of Difference in Children`s 
Retention in Care. 









1 0.87  0.92 0.05 316 
2 0.87 0.93 0.06 213 
3 0.87 0.94 0.07 151 
4 0.87 0.95 0.08 111 
  
We would like to be certain that the difference is not more than 5%, which requires a sample 
size of at least 316. However, based on preliminary analysis of RCWMCH data, 725 children 
transferred out to a Western Cape lower level health facility during the study period. We 
therefore expect to have >80% power to detect difference in retention of at least 5% from our 
null hypothesis of 87% retention. 
7 Measurement 
Analysis will be done on the following existing measurements that were taken during the 
routine ART programme: 
7.1 Children`s Characteristics at Transfer out Date 
This shall include markers of disease severity of viral load (copies/mL) and CD4 count or 
percentage at transfer out date to a lower level health facility for the continuation of ART. (i.e 
laboratory test performed closest to the transfer out date within a window of 12 months before 
date of transfer out from RCWMCH). Likewise, their characteristics at ART initiation and 
duration on ART before transfer out will be included. Date at which each test was conducted 
will be recorded. Table 3 below. 
7.2 Children`s Characteristics at Referral Facilities. 
This shall include patient’s markers of disease severity of viral load (copies/mL) and CD4 
count or percentage performed at patient’s first appointment/contact with referred lower level 
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health facilities. The median time from transfer date to first laboratory information at referral 
facilities will also be recorded Table 4 below. 
Dummy Tables 
Table 3: Children Characteristics at Transfer out. 
Characteristic Data 
Age in months at ART start Median (Interquartile range) 
Gender Male – n, %, Female – n, % 
The proportion of children 
immune suppressed at ART 
start. 
Yes - n, %, No – n, % 
The proportion of children 
with advanced WHO disease 
at ART start (WHO clinical 
stage 3 or 4) 
Yes - n, %, No – n, % 
Growth measurement of 
Weight for age z-score at ART 
start. 
<-3 SD n, % 
< -3 to -2 SD    n, %
>-2 SD n, % 
The proportion of children 
virologically suppressed at 
transfer (copies/mL). 
Yes – n, %, No – n, % 
The median CD4 count 
(cells/μl) or percentage status 
at transfer. 
Median (Interquartile range) 
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Duration of time (months) on 
ART before transfer. 
Median (Interquartile range) 
 
Table 4:Children Characteristics at Referral Facilities. 
Characteristic Data 
Median time (months) from 
transfer date to first laboratory 
data at a referral facility. 
Median (Interquartile range) 
First CD4 count (cells/μl) data 
at referral site after transfer 
out date. 
Median (Interquartile range) 
The proportion virological 
suppressed at first visit at 
referral site after transfer out 
date (copies/mL). 
Yes – n, %, No – n, % 
The proportion of children 
immune suppressed at referral 
site after transfer out date 
Yes – n, %, No – n, % 
 
7.3 Validity and Reliability of Measuring Instruments 
The validity of the data in the RCWMCH database is dependent on the recording of information 
at the site, and the validity of the laboratory data from other sites is dependent on data quality 
in the NHLS Provincial Database. The NHLS data will be used to measure successful transfer 
of children at referral sites after they were transferred out from RCWMCH. This laboratory 
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data has been reported to be effective in monitoring trends in early infant diagnosis of women 
on the prevention of mother to child transmission programme of SA (45). It is also noteworthy 
that a recent report on the short-term outcomes of children < 13 years that were initiated onto 
ART at RCWMCH intensive care unit assessed the outcomes of transferred children using 
NHLS data (41). Similarly, the outcomes of children < 15 years transferred out from Tygerberg 
Hospital (one of the three tertiary health facilities in Western Cape Province) were assessed 
using data on the NHLS server (40). Data cleaning and quality control routines will be 
implemented to enhance data validity. 
8 Statistical Methods 
8.1 Data Access 
The NHLS performs all HIV-related laboratory tests for SA public health facilities. Its national 
network of > 260 laboratories provides services for those without medical insurance (about 
85% of the SA population) (45). The RCWMCH linkage to Western Cape Provincial laboratory 
database will be used to monitor the transition and clinical outcomes of children transferred 
out from RCWMCH from between December 31, 2007 and January 1, 2012. 
8.2 Data Linkage 
The RCWMCH children records were deterministically linked to Western Cape Provincial 
laboratory database using patient’s folder number, date of birth and name by provincial staff. 
The integration of RCWMCH programme with the Western Cape programme has been 
described in previous publications (24, 25).  
8.3 Data Cleaning 
Data cleaning will be undertaken by the researcher. The anonymized linked dataset will be 
transferred to the researcher in STATA for cleaning and analysis. First, patients’ records will 
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be assessed to determine whether transfer was successful or not. A successful transfer will be 
defined as a RCWMCH transferred out child with a linked laboratory result record within 18 
or 48 months after the transfer date from RCWMCH.  
In contrast, RCWMCH transferred out children without laboratory information within 18 or 48 
months of transfer out date from RCWMCH will be considered not to have successfully 
transferred.  
The primary outcome of successful transfer was defined in two ways: a laboratory test 
performed by a lower level facility (i) ≤18 months or (ii) ≤48 months after the transfer date. 
The first interval corresponds to guideline recommendations for annual CD4/viral load 
monitoring; the second captures all children retained in care.  
In addition, in children with laboratory results available from a transfer site within 18 months 
of transfer (i.e. successful transfers) we will assess whether the site from which the post-
transfer sample was collected is in fact the site to which the child was transferred or a site that 
is in close proximity to the child’s home address. 
8.4 Descriptive Analysis 
The analysis will be done using both univariate and multivariate methods. The characteristics 
of children at ART start and before transfer out as well as within 18 months of transfer out will 
be described using means and standard deviation for normally distributed continuous variables 
and medians and interquartile range for non-normally distributed continuous variables. 
Categorical variables will be summarized using proportions and differences between patient’ 
subgroups and will be compared using chi-squared tests or Fisher’s exact tests if one or more 
cells have an expected frequency less than five.  
Continuous variables will be assessed for normality using histograms and the Shapiro-Wilk 
test. Paired Wilcoxon signed rank test will be used to assess if there is any significant difference 
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between individual repeated measures of CD4 percentage/count and viral load if any of these 
variables is not normally distributed. A paired t-test for the difference between paired samples 
will be used if they are normally distributed. 
8.5 Sensitivity Analysis 
A sensitivity analysis will be carried out to determine the potential impact of uncertainty around 
the pre-specified window of 18 months allowed for successful transfer. We will examine the 
impact on the proportion of children deemed to have successfully transferred using longer and 
shorter thresholds (e.g 15 months, 18 months, and 48 months). These intervals were selected 
to examine if the proportion of successful transfer differs substantially when reducing or 
increasing the successful transfer window after transfer out date. 
8.6 Logistic Regression Model 
Multivariate logistic regression will be used to identify patient characteristics that are 
associated with successful transfer. A multivariate logistic regression will be built by 
sequentially adding variables considered a priori to be potentially associated with successful 
transfer based on evidence from the literature. For example, age has been described as a strong 
prognostic factor for children’s outcomes (44). Therefore, age will be firstly introduced into 
the model, followed by other potential prognostic variables such as duration on ART, gender 
and most recent laboratory information (CD4 counts/percentage) of children (25). Any variable 
with a p-value < 0.1 after adjustment for the variables already in the model or that changes the 
odds ratio of variables already in the model by ≥ 10% will be retained. No cut-off for p-value 
will be used to define statistical significance as all p-values for all the analysis will be reported 
exactly (46).  
The log-likelihood ratio test will be used to compare nested models and Alkaike's information 
criterion (AIC) to compare non-nested models. Best model fitness will be assessed using 
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Hosmer and Lemeshow goodness of fit test. All analyses will be two sided at an alpha of 0.05. 
Stata statistical software, version 14.1 will be used for analysis (47). 
9 Ethics Considerations 
This study aims to abide by the ethical principles of health research that include justice, 
beneficence, and autonomy. This study will seek ethical approval from University of Cape 
Town Human Research Ethics Committee (HREC) before proceeding. 
9.1 Autonomy 
This study will not require patient informed consent as the data collected for analysis was from 
routine operational monitoring data. Even though this study dataset will be extracted from the 
RCWMCH, utmost confidentiality of patient information is guaranteed because the extraction 
was done by the staff that provided patient clinical care and are responsible for data capture at 
the sites.  
The dataset for analysis in this study has existing UCT HREC approval (REC REF: 261/2002) 
(Appendix B and C). In addition, provincial approval was obtained to link RCWMCH data to 
the Western Cape Provincial data warehouse in order to evaluate outcomes in their own patients 
(Appendix A). This was a deterministic linkage using identifiers such as folder number, name, 
and date of birth and was performed by provincial staff with permission to access identified 
data. The researcher will not have access to patient information details as all patients’ 
identifying details have been removed and replaced with anonymized identifiers. 
The analysis dataset will be securely stored on the student's computer in a password-protected 
folder. On completion of analysis, after manuscripts have been accepted for publication, the 
analysis dataset will be returned to UCT for secure archiving by the School of Public Health 
and Family Medicine and the copy on the student`s computer will be permanently deleted. 
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Since this study is a secondary analysis of previously collected data, no additional laboratory 
tests will be conducted. 
In all cases, individual level information will not be reported but aggregate level results will be 
reported in any paper that may arise from this work. 
9.2 Beneficence and Justice 
The results of this study would be useful for designing interventions aimed at reducing attrition 
during transfers in the ART continuum of care for HIV-infected children of Western Cape, SA. 
Participants will not benefit directly from the outcomes of this study; however, the results can 
be used to improve care for the population of children represented in this study. Therefore, 
justice is achieved. 
This study will be done in accordance with the 64th assembly of World Medication Association 
Declaration of Helsinki (48) and ethical regulations of SA. 
10 Stakeholders 
Stakeholders will include staff at RCWMCH and other treatment sites providing ART care to 
children transferred out from RCWMCH within the Western Cape Province, SA. Stakeholders 
also include children and caregivers attending those sites, the academic community, and policy 
makers in the field of paediatric ART. 
11 Dissemination of Study Results 
Results of this study will be made available and accessible to researchers in the field of 
infectious disease by publishing results in the form of a manuscript in a peer-reviewed journal 
that will be identified. The results of the study will also be made available to the staff at 
RCWMCH. The results of this study have a good prospect to influence Western Cape Province 
paediatric ART policy.  
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Table 5: Timetable for Completion of Mini-dissertation. 
Task Duration 
Protocol Development December 2014 – March 2016 
Literature Review  May 2014 – July 2016 
Data management  August 2016 
Analysis  August – September 2016 
Write-up September – January 2017 
Dissemination to stakeholders February 2017 
Submission March 2017 
 
12 Budget 
Since this will be a secondary analysis of routinely collected data, no anticipated costs are 
expected during the course of this study. The student researcher will conduct the analysis free 
of charge. 
13 Study Limitations 
1. Due to the design of this study as a retrospective observational study and because 
routine programme data will be utilized, any existing deficiencies in the accuracy and 
consistency of routine data will be a limitation. 
2. Survivor bias will also be of concern since patients are expected to be clinically stable 
before transfer out from RCWMCH. Consequently, the study results will apply to a 
cohort of children with severe disease who were initiated onto ART at a tertiary hospital 
and who survived and became stable on treatment prior to transfer. Therefore, the 
generalizability of the study results will be limited to children with similar 
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characteristics. Similarly, the study sites that were included in this study are Western 
Cape Province lower level health care facilities providing ART services for children 
transferred out from RCWMCH. Thus, the generalizability of this study results to 
children transferring in other provinces may be limited. 
3. The estimated proportion of children successfully transferring in our study might be an 
artefact of our measuring tool of successful transfer i.e. NHLS data. The information 
provided by this data is consequent on patient’s presentation at the transferred out lower 
level health facilities within Western Cape, SA and a laboratory test being performed 
according to national guidelines. If tests were not performed according to the national 
guidelines (i.e viral load done less frequently than recommended), we may 
underestimate transfer in children who actually transferred in successfully at referral 
sites but have not had laboratory monitoring performed as per guidelines. The use of a 
window of up to 18 months after transfer for a laboratory test in order for a child to be 
considered “successfully transferred” reduces this limitation, as does our sensitivity 
analysis which will examine how the duration of the allowable window after transfer 
affects the proportion of children deemed to have successfully transferred. Our study 
does not address passive or silent transfers of patients within or outside Western Cape 
lower health care facilities and hence cannot comment on overall retention in care at 
the level of the programme. However, the focus of our study is on successful transfer 
to the facility that a patient was referred to, rather than overall retention. In addition, 
we will not be able to ascertain the reasons for patients not transferring successfully, 
which may include death. There are many factors associated with the successful transfer 
of patients and we will only be able to examine factors that have been recorded in the 
RCWMCH electronic database. For example, we will be unable to explore whether 
socio-economic status, disclosure to the child or to other caregivers, caregiver education 
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In a move to remove the barriers of patients’ access to Human Immunodeficiency Virus (HIV) care in 
low and middle-income countries (LMICs), the World Health Organization (WHO) recommended a public 
health approach for expanding antiretroviral therapy (ART) care in resource-limited settings. The multi-
pronged approach includes - decentralization of ART services and task shifting which is a triage model for 
ART management of people living with HIV. Due to the urgency of scaling up ART in LMICs, both 
approaches are implemented in parallel to scale up HIV care in most LMICs (1-3).    
The effectiveness of decentralized ART care in adults has been reported in the literature. These models of ART 
delivery have consistently been demonstrated to be effective for removing the barriers of patients’ access to 
care in LMICs, and at improving the outcomes of patients (4-7). To address similar challenges in children, 
decentralization of ART care for children has been implemented in LMICs. Limited evidence in the literature 
suggests the use of decentralization models for scaling up paediatric ART care in LMICs improves the clinical, 
immunological and virological outcomes of children in ART programmes  (8-10).  
Due to the increasing use of decentralized models for ART care, Kredo et al (2013) (4) have categorized the 
different decentralization models used to scale up ART services in LMICs based on the evidence from the 
literature. Models of ART care adopted in different settings might be indicative of their human resource 
capacity (2, 11), and have been grouped into three broad categories;  
1. A full decentralization model of ART care:  Comprehensive ART services are provided for patients at 
any level of health facilities. The services provided range from ART initiation and patients’ continued 
ART management at the same health facility. 
2. A partial decentralization model of ART care: Patients are initiated on ART at higher level health care 
facilities before being transferred to lower level facilities for the continuation of ART care. 
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3. Community decentralization model of ART care: This model of ART care involves initiating patients
on ART at either lower or higher level facilities before being transferred out to the community for
continuation of care.
For the purpose of literature comparability, this review will focus on literature reporting on the outcomes of 
patients transferring care in order to be relevant with the aims and objectives of our study which focuses on the 
outcomes of children transferring out of Red Cross War Memorial Children’s Hospital (RCWMCH). Based 
on the different decentralization ART models described above, the studies reviewed therefore include partial 
and community decentralization models of HIV care since these models include the transfer of patients 
between ART treatment sites.  
A review of the literature reporting on the outcomes of transferring patients will provide insight on existing 
knowledge about the outcomes of these models of ART care and evidence gaps with respect to outcomes of 
patients transferring care between facilities. 
2.1 Aims and Objectives 
This review aims to appraise the current literature on patients transferring between facilities for 
HIV care, with the aim to place our/my study within the context of other studies in this research 
area and identifying gaps for future research. 
The specific review objectives are as follows: 
1. To identify all published literature reporting on the outcomes of transferring HIV-infected
patients on ART in LMICs.
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2. To describe the evidence in the above published literature by synthesizing and critically 
examining the quality of evidence regarding the outcomes of patients transferring between 
ART sites in LMICs. 
3. To identify questions that emerge on patient transfer that could form the basis for further 
research. 
3       Review Process 
This review will make the process of literature search, quality and comparability assessment 
of all the studies identified explicit. The presentation of the findings of these studies will follow 
an organized and logical format. Therefore, the presentation layout for this review will include 
the characteristics of patients at ART initiation, outcomes of transferring patients in the HIV 
continuum of care, predictors of successful transfer, methodological approaches used for the 
assessment of successful transfer and loss to care. Results validity and study quality will also 
be discussed.  
3.1       Search Strategy 
Multifaceted Boolean searches of the Medline bibliographic database using the PubMed 
interface (National Library of Medicine, Bethesda, MD) and the Scopus (Embase bibliography 
database) electronic database were performed simultaneously.  
The search strategy started by combining all sets of key terms under the following Medical 
Subject Headings (MeSH) to identify literature on HIV infected participants: “HIV" OR 




To identify literature on decentralization models of ART care for HIV infected patients the 
following key terms were combined: “Down referral" OR “HIV continuum of care" OR 
“decentralization" OR “retention in care" OR “transfer out" OR “task shifting" OR “connection 
to care".  
Then, to identify literature on HIV infected participants receiving ART the following MeSH 
key terms were combined: “Antiretroviral" OR “antiretroviral therapy" OR “ART" OR 
“HAART" OR “ARV" OR “cART".  
Also, to identify literature on the outcomes of HIV-infected participants on ART the following 
key terms were combined “outcome" OR “suppression" OR “mortality" OR “survival" OR 
“effect" OR “health" OR “effectiveness" NOT “maternal” NOT “PMTCT" NOT “MTCT" 
NOT “maternity" NOT “cure" NOT “pregnancy" NOT “pregnant".  
Furthermore, to  identify studies from LMICs the following key terms were combined based 
on World Bank classification of LMICs and MeSH key terms (12): “Africa" OR “Asia" OR 
“Caribbean region" OR “Central region" OR “Central America" OR “Latin America" OR 
“South America" OR “Southern Africa" OR “Sub Saharan" OR “middle income countries" OR 
“low and middle income countries" OR “resource limited" OR “resource constrained" OR 
“developing countries.  
Lastly, the five sets of specific terms searched were combined together using the AND operator 




3.2 Inclusion Criteria 
 All published articles written in English from LMICs reporting on outcomes of 
transferring patients in the HIV continuum of care were included. This review was not 
limited to paediatric studies; adult studies were included because the literature reporting 
on outcomes of children transferring between higher level facilities and lower level 
facilities in LMICs is extremely limited.  
 The outcomes included were mortality, immunological and virological outcome, loss 
to care, successful transfer, loss to follow-up (LTFU), adherence. 
 Studies reporting on outcomes of transferring patients that were ART-naïve at ART 
initiation were included. 
 Observational studies were included in this review, which comprised of both 
descriptive and analytic studies. More recent studies (published in the past 10 years 
[January 2006 to July 2016]) were given priority. 
3.3 Exclusion Criteria 
 Studies reporting only on patients’ outcomes in a full decentralization model of ART care. 
 Studies reporting on outcomes of transferring patients in highly specified patient groups 
e.g. commercial sex workers or senior citizens. 
 Studies reporting pre-ART outcomes of patients regardless of the model of ART care. 
 Randomized control trials, qualitative studies and studies from high-income countries. 
The bibliographies of all the literature that met the inclusion criteria were further examined based 
on the inclusion criteria used for the initial literature search from in PubMed and Scopus database. 
This led to the inclusion of two additional studies, which met the inclusion criteria. 
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Figure 1: Flow diagram of the studies included in this review. 
 
 
3.4 Articles published 
The search strategy presented above yielded 981 published articles in PubMed and Scopus. 
However, only fifteen studies met the pre-specified inclusion criteria after removing studies that 
overlapped between the two databases. Two additional studies from the bibliography search of the 
initial studies selected were subsequently included after meeting the pre-specified eligibility 
criteria. One study by Bock et al (2008) was included in this review although it primarily aimed to 
compare outcomes of patients at different levels of care in a full decentralization model of ART 
care (13). However, this study also captured the information of children transferred out to lower 
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level facilities for continuation of ART care and these children were subsequently included in the 
study analysis. This study was included because of the sparse literature reporting on the outcomes 
of children transferring in the HIV continuum of care. In addition, two studies that reported the 
outcomes of patients in a community decentralization model of ART care were included in this 
review because both met the inclusion criteria (14, 15). 
4 Quality and Comparability of study 
Patient characteristics relevant to the study research questions were extracted and presented in 
tables. The quality of the studies included was assessed in terms of the aim and scope of the study. 
The quality criteria included were: study design, sample size and treatment initiation guidelines 
followed (Tables 1–2c). 
Different studies were described and compared in terms of the model of ART care, year of study, 
follow-up time, patients’ immunovirological characteristics at ART initiation or at transfer, 
patient’s eligibility criteria before transfer out as well as how missing and incomplete outcomes 
were managed. 
4.1 Primary aims and focus of the study 
Of the seventeen studies that were identified and included in this review, only four studies 
comprised entirely child participants (10, 13, 16, 17). Eleven studies only included adults (14, 15, 
18-26), while children accounted for a proportion of patients’ in two studies, 11.5% (Yu et al 2008) 
and 9.61% (Chan et al 2010) respectively (27, 28).  
All but two studies included in this review are from sub-Saharan Africa. Hansudeweschakul et al 
(2012) reported on the outcomes of children in Thailand while Ghate et al (2014) reported on the 
outcomes of adult patients’ transferring between ART treatment sites in India (10, 21). The 
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majority of the studies reported both on transfers and task-shifting for the provision of HIV 
treatment and care. 
Characteristics of patients transferred out are reported at the time of transfer or at ART initiation 
where possible. Ten of the seventeen studies were comparative in design, comparing the outcomes 
of patients who started ART at the higher level facilities and continued to be managed there with 
the outcomes of patients who transferred out to lower level facilities for continuation of ART care. 
4.2 Study design 
All the studies reviewed were observational studies in line with the inclusion criteria. The majority 
of the studies used data collected retrospectively. However, Colasanti et al (2016) used 
prospectively collected data for their analysis. 
Five studies were descriptive in design and reported on the outcomes of transferring patients in the 
HIV continuum of care (14, 20, 21, 24, 26). Colasanti et al (2016) conducted a secondary analysis 
of a case (virologic failure)-control (no virologic failure) study using individual-level factors 
collected from patients prospectively to assess the predictors of not being in care (25). Most studies 
used analytical methods to assess the outcomes of their patients.  
4.3 Sample size 
No study provided sample size calculations for the number of participants included, but rather 
included all eligible participants based on their pre-specified eligibility criteria. The sample size 
of adult studies ranges from 158 – 8,093, while that of paediatric studies is generally lower (range 
109 – 1741).  
 
9 
4.4 Follow-up duration 
Because of the scope of the studies included in this review, follow-up time was reported in a variety 
of ways. While some studies reported follow-up time of patients before transfer out to lower level 
facilities, others reported patient follow-up time only at transferred out sites before the assessment 
of outcomes.  
Brennan et al (2013) specifically ensured that both transferred out patients and patients managed 
at the initial treatment site had comparable follow-up time before the assessment of their study 
outcomes. To achieve this, time zero for participants was defined as the time at which patients 
became eligible for transfer out based on improvement in their immunovirological outcomes 
regardless of whether they were actually transferred out. Thereafter, person-time accrued from 
time zero to the earliest outcome of interest (18). 
The follow-up duration of patients was relatively long in both paediatric and adult studies (ranges 
18-40 months and 12-60 months respectively). However, the Indian study did not report patient 
duration of follow-up (21). 
4.5 Study Population and Initiation Guideline 
Patients were all ART-naïve at ART initiation except for the study from Thailand that reported 
about 90% of study participants were ART-naïve at initiation (10). Nevertheless, ART-
experienced patients were excluded from their sub-analysis to prevent potential bias in patient 
outcomes. The age threshold used to define children differs across the studies ranging from less 
than 14 to less than 16 years (10, 13, 17, 29). Two adult studies reported a threshold defining 
adults, namely those ≥ 18 years of age in these studies (18, 19). 
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The studies included in this review utilized routine data sources, i.e. data were collected prior to 
the development of research questions. The inclusion criterion used in these studies was essentially 
ART-naïve patients who are eligible for ART at the time of initiation. Importantly, all patients’ 
were initiated on ART using their setting’s HIV/AIDS management guidelines adopted from WHO 
HIV/AIDS management guidelines (30).  
All but two studies participants were managed at public health facilities operated by the 
government. In the studies by Cloete et al (2014) and Colasanti et al (2016) participants were 
initiated on ART at a semi-private, government-subsidized clinic with partial Presidents 
Emergency Plan for AIDS Relief (PEPFAR) funding. Patients paid a monthly fee of $18 (25, 26). 
Thus, the results from these studies might not be completely generalizable to public health facility 
settings.  
4.6 Model of ART care 
The decentralization of HIV-infected patients on ART to lower level facilities for continuation of 
care is an intervention geared towards expanding HIV care coverage in LMICs and is an alternative 
to the continued management of patients at already overstretched higher level facilities in LMICs.  
In most studies, stable patients were transferred to lower level facilities for continuation of care 
and patients could be transferred back to higher level facilities if the need arose due to failure in 
health status, poor adherence and for the management of adverse events as per partial 
decentralization (10, 18, 29). However, in two studies transfer of patients to public health facilities 
was mandatory irrespective of their clinical status due to shortage of funding at the initiation 
facility (25, 26). The community decentralization studies allowed for the transfer out of stable 
patients to the community in form of self-forming ART adherence club (14, 15).  
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In both decentralization models described, higher level facility staffs in some settings provided 
continued support, monitoring and mentoring to lower level facility staffs (13, 15, 17, 18, 27, 29).  
4.7 Transfer out eligibility 
Patients’ were generally defined as being eligible for transfer when stable on ART at treatment 
initiation sites (mostly higher level facilities) in terms of their clinical status improvement. In 
addition, the absence of opportunistic infections and, in some cases, demonstrated high level of 
adherence to treatment were used to identify patients for transfer out to lower level facilities. These 
eligibility criteria may give rise to survival bias with better outcomes in those transferring out. 
In some studies, patients were required to have been on ART for a specified period before 
becoming eligible for transfer. This period varied across studies from 3 months (27, 29, 31) to 6 
months (14, 20) and up to 18 months (15, 18, 19). Some paediatric studies also required parents to 
consent to the transfer option (10, 17, 29).  
4.8 Confounders 
Unmeasured confounding is of concern for almost all the studies included in this review. In 
particular, patient socio-economic information may impact outcomes after transfer out and was 
not measured in most of the studies included. However, most studies did attempt to adjust for 
possible confounding variables at the analysis stage using multivariate regression analyses. It is 
worth noting that, confounding was addressed at the design stage of two studies by including 
transferred out and non-transferred patients in a 1:3 ratio matched on probable confounding 
variables of age, gender, time on ART, ARV regimen at study eligibility and CD4 count at study 
eligibility. Propensity scores were used to achieve comparable baseline characteristics in patients 
transferred out compared to patients remaining at the treatment initiation site (18, 19). 
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Nevertheless, Brennan et al (2011) also conducted a sensitivity analysis to assess the potential 
impact of unmeasured confounders on the outcomes of patients transferred out to lower level 
facilities compared to those managed at the treatment initiation site. This analysis showed that 
patients’ managed at the treatment initiation site are more likely to have their estimates biased 
towards the null by unmeasured confounders compared to those transferred out (45% versus 1%) 
respectively. This underscores the vulnerability of the results of observational studies to be biased 
by confounding variables. This study also assessed the possibility of effect modification of their 
results by stratifying the effect measures by plausible confounding variables of gender and CD4 
count (≥ 350 cells/m𝑚3 versus 200-349 cells/m𝑚3) (18).  
4.9 Missing data 
Due to the retrospective design of all the studies included in this review and the utilization of 
routine data, some level of data missingness is expected. However, the extent and potential impact 
of missingness on effect estimates reported in these studies are paramount to addressing internal 
validity of the results reported since this can be a source of bias. Most studies included only patients 
with complete data on the outcome and exposure variables of interest. Of note, one of the studies 
included which reported substantial level of missing data on patient viral load data used multiple 
imputation under the assumption that the data are missing at random (10, 32-34). In contrast, 
another study presented the number of missing data in their study and highlighted the fact that 
patients with missing data that were excluded from their analysis had similar characteristics to 
patients included in their analysis (18)
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Table 3: Characteristics of children at ART initiation.                                                        




Bock et al (2008) NR NR 
% with CD4 percentage <15% (CI) 
Higher level facilities 
48.1 (CI 36-52) 
Intermediate level facilities 
52.1 (CI 36-52) 
Lower level facilities 
35.5 (CI 31-41) 
 
 
NR NR NR 
Hansudewechakul et al 
(2012) 
See table 1 
Higher level facility 
85.7% overall CDC HIV clinical 
stage 
Stage N or A 51(38%) 
Stage B 30(23%) 
Stage C 33(25%) 
Lower level facilities 
90.26% overall CDC HIV clinical 
stage 
Stage N or A 50(32%) 
Stage B 28(18%) 
Stage C 61(40%) 
 
Higher level facility 
Median CD4% 
6 (IQR 2-12) 
Lower level facilities 
Median CD4% 
5 (IQR 2-11) 
 
 
Higher level facility 
(copies/ml) 
(available in 38 patients) 
133,570 (IQR 49380-230700) 
 
Lower level facilities 
(copies/mL) 
(available in 22 patients) 
80400(IQR 17622-153032) 
Higher level facility 
Median WAZ score (%) 
-1.6 (IQR -2.6 to -0.8) 
Lower level facilities 
Median WAZ score (%) 
-2.1 (IQR -2.8 to -1.5) 
NR 




Severe immunosuppression (%) 
Higher level facility 
23(62.2%) 







See table 1 
NR 
Higher level facility 
Median WAZ score (%) 
-1.7 (IQR -2.5 to -0.7) 
Lower level facilities 
Median WAZ score (%) 
-2.3 (IQR -3.6 to -1.3) 
 
NR 
Morsheimer et al (2014) 
 
 
See table 1 
Down referred on ART to lower 
level facilities 
WHO clinical stage (%) 
89.8 stage III/IV 
See table 1 
Down referred on ART to 
lower level facilities 







Down referred on 




NR: Not reported, CI: Confidence interval, IQR: Interquartile range, TB: Tuberculosis, WHO: World Health Organization, ART: Antiretroviral therapy, VS: versus, VL: viral load, sd: standard 
deviation, WAZ: Weight for age z score, HAZ: height for age z-score. 
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Table 4: Characteristics of adults at ART initiation continued.                                                        




Chan et al (2010) See table 2a 
Higher level facility 
WHO clinical stage (%) 
Stage 3 2394 (51.5) 
Stage 4 1076 (23.1) 
 
Lower level facilities 
Stage 3 1906 (55.4) 










Brennan et al (2011) 
See table 2a 
 
 
Higher level facility 
WHO clinical stage (%) 
Stage 3 792 (38.1) 
Stage 4 120 (5.8) 
 
Lower level facilities 
Stage 3 254 (36.7) 




Higher level facility 
Median CD4 count 
Median CD4 count cells/𝑚𝑚3 
101 (IQR 40-168) 
Lower level facilities 
Median CD4 count cells/𝑚𝑚3 
108 (IQR 43-168) 
 
Higher level facility 
362 (17.4%) 
Lower level facilities 
104 (15.0%) 
 
Long et al (2011) See table 2a 
NR 
 
Higher level facility 
Median CD4 count cells/𝑚𝑚3 94 
(IQR 36-163) 
Lower level facilities 


















5 Patient characteristics at ART initiation/transfer out  
The tables (1-4) above summarize the characteristics of patients included in this review at ART 
initiation or at transfer out. Patient-level variables of age, HIV/AIDS WHO/Center for Disease 
Control and Prevention (CDC) clinical stage, and immunovirological status were commonly 
reported in both adult and paediatric studies. These characteristics were mostly comparable 
between patients managed at higher level facilities compared to those transferred out to lower level 
facilities for continuation of HIV care. In general, nine studies reported the regimen used by their 
patients (10, 18-20, 22, 23, 29). In addition, two paediatric studies reported weight-for-age z-score 
(WAZ) in their patients (10, 29). 
The quasi-experimental design method adopted by South Africa (SA) studies (18) and (19) ensured 
comparable characteristics in patients at transfer out eligibility. Other patients characteristics 
reported at ART initiation was the prevalence of HIV co-morbidity with tuberculosis and this was 
reported in two studies: one paediatric and one adult study (17, 18).  
 
5.1 Age 
All but one paediatric study included in this review reported the median/mean age of their 
participants (35). In the Zambian study, the median age of children transferred out to lower level 
facilities was younger 2.9 years (IQR 1.7-7.3 years) compared to those managed at a higher level 
facility 5.9 years (IQR 2.4-10.4 years), suggesting that younger children were more likely to be 
transferred out (29). While age was comparable between those transferring out and those 
remaining at the initiation site in other studies, the age of children included in each study was very 
different. In a Thailand study, the median age was 8.6 years raising the question of generalizability 
to younger children. In contrast, a study conducted in the Western Cape Province of SA utilizing 
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routine data from one of the three tertiary hospitals in Cape Town (Tygerberg Children’s Hospital) 
had the youngest participants with cohort median age of 25.1 months (IQR: 10.5 – 59.3 years) 
(17). Age at transfer out is a key consideration in children because of rapid early disease 
progression in younger children (36).  
 
In the adult studies included in this review age was comparable irrespective of where patients 
received HIV care. The median age of the adult participants at ART initiation across the studies 
included in this review ranged from 32.9 years to 38.5 years (15, 19).  
 
5.2 Virological status  
Only a handful of studies reported viral load measurements due to the lack of capacity for viral 
load monitoring in most LMICs. Among paediatric studies, the Thailand study reported a lower 
median viral load (copies/mL) of 80 400 copies/mL (IQR 17 622 – 153 022 copies/mL) in 22 
patients’ transferred out to lower level facilities compared to 133 570 copies/mL (IQR 49 380 – 
230 700 copies/mL) in 38 patients’ managed at higher level facilities at ART initiation (10). This 
difference is probably because sicker patients tend to be managed at higher level facilities before 
being transferred out to lower level facilities for continued HIV care. However, the number of 
patients with viral load measurements was quite small at both levels of health care. In the same 
vein, in the Tygerberg children’s hospital study, the median viral load at ART initiation was 326 
969 copies/mL (IQR 87 841 – 1 554 457 copies/mL) in children transferred out to lower level 
facilities compared to 230 000 copies/mL(IQR 32 000 – 830 000 copies/mL) in patients initiated 




No adult study reported viral load measurements at ART initiation. However, Luque-Fernandez et 
al (2013) reported that 2501 (88.4%) of their patients were virologically suppressed before 
adherence club participation. The high proportion of virologically suppressed patients might be 
due to the fact only stable patients were presented with the option of adherence club (15).  
 
5.3 Immunological status  
CD4 count, percentage or both measures were reported in most studies included in this review. 
Paediatric studies mostly reported CD4 percentage:  
The Thailand paediatric study, reported comparable but very low median (IQR) CD4% among 
children managed at higher level facility and those transferred out to lower level facilities (6% 
(IQR 2-12%) vs 5% (IQR 2-11%)) respectively (10). A Zambian paediatric study reported 
comparable but higher median CD4% among patients’ managed at higher and lower levels 
facilities (14.4% (IQR 11.0–19.5%) and 14.2% (IQR 10.5 – 18.9%)) respectively at ART initiation 
(29). However, children transferred out from Tygerberg children’s hospital had a slightly higher 
overall CD4% of 16%  (IQR 10.0 – 21.8) at ART initiation (17).  
 
In adult studies, the median CD4 counts of patients’ at ART initiation were generally low. The 
vast majority of patients had CD4 count cells of < 350 cells/𝑚𝑚3 at initiation in line with the 2010 
WHO ART guidelines recommendation that adults living with HIV with CD4 count cells of < 350 
cells/𝑚𝑚3 should be started on ART (37). Median CD4 count in the different studies  ranged from 
94 cells/𝑚𝑚3 (19) – 202 cells/𝑚𝑚3 (15). CD4 count characteristics were similar for patients’ 
managed at either level of health care.  
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5.4 Clinical disease classification 
The WHO classification of disease status was used in all but one study included in this review 
(38). The latter study used the 1993 CDC classification to assess the severity of HIV disease (10, 
39). The Tygerberg children’s hospital study found that nearly 90% of children transferred out to 
lower level facilities had advanced/severe clinical status of HIV disease at ART initiation (17). In 
addition, 40% (61/154) of children transferred out to lower level facilities were classified to have 
severe HIV disease at ART initiation based on CDC clinical staging compared to 25% (33/133) of 
children managed at a higher level facility in Thailand (10). 
Among adult patients, those managed at higher level facilities had relatively better clinical status 
at ART initiation compared to patients’ transferred out to lower level facilities. For example, the 
Indian study reported that 84% of patients managed at higher level facilities had WHO clinical 
stage 3 or 4 disease compared to about 93% of patients transferred out to lower level facilities at 
ART initiation (28).  
5.5 Presence of tuberculosis. 
Only one paediatric study and one adult study reported the proportion of their patients’ with 
tuberculosis co-infection (17, 19). Among children who initiated ART at Tygerberg children’s 
hospital, 25.3% of them had tuberculosis co-infection at ART initiation (17) and Brennan et al 
(2011) reported 17.4% prevalence of tuberculosis co-infection in patients’ managed at higher level 




Child growth was assessed using weight-for-age Z-score (WAZ) in two paediatric studies. The 
Thailand paediatric study, calculated WAZ using the Thailand national standards for height and 
weight adapted from WHO guidelines and reported a median WAZ of -1.6  (IQR -2.6 to -0.8 ) in 
children managed at a higher level facility compared to -2.1 (IQR -2.8 to -1.5) for those transferred 
out to lower level facilities at ART initiation (10, 40). In Zambia, using WHO growth reference 
standards the median WAZ was -1.7 (IQR -2.5 to -0.7 ) in children managed at higher level facility 
compared to -2.3 (IQR -3.6 to -1.3 ) for those transferred out to lower level facilities at ART 
initiation (29). These results suggest that children managed at higher level facilities had better 
nutritional status at ART initiation compared to those transferred out to lower level facilities. 
 
5.7 Anemia 
Anemia is a risk factor for death in HIV-infected patients and this can occur at any clinical stage 
of the disease (41, 42). Only Brennan et al (2011) reported the haemoglobin of their patients at 
ART initiation. Patients managed at higher level facility median haemoglobin was 13.8 ug/dL 
(IQR 12.9 – 14.9 ug/dL) compared to 14.1 ug/dL (IQR 13.1–15.2 ug/dL) in patients transferred 
out to lower level facilities (18).  
 
5.8 Regimen 
First-line ART regimens were reported by a number of the studies reviewed. The most commonly 
used first-line regimen was two nucleoside reverse transcriptase inhibitors (NRTI) with a non-
nucleoside reverse transcriptase inhibitors (NNRTI) regimen (10, 18-20, 22, 23, 29). Two studies 
excluded patients’ on second line regimens (18, 22), and a paediatric study excluded patients 
 
24 
initiated on protease inhibitor-based regimens to account for potential bias in patients’ 
immunological and virological status (10). 
 
In general,  patients had improved immunovirological and clinical characteristics at transfer out 
compared to ART initiation characteristics in both paediatric and adult studies (10, 18, 19, 23, 26). 
 
25 







Loss to follow-up Virological Immunological (CD4) Adherence 
Bock et al (2008) 18 months 
Incidence rate ratio of 
PHC Vs level 2 & 3 
children 
6m: aIRR 0.33 p< 0.001) 
12m: aIRR 0.39 p< 0.003) 
18m: aIRR 0.38 p< 0.018) 
 
 
Survival (Death & LTFU) 
Higher level facilities 
6m: 0.91(CI 0.89-0.93) 
12m:0.88(CI 0.86-0.91) 
18m: 0.85(CI 0.81-0.88) 
District level facilities 
6m:  0.96(CI 0.91-0.98) 
12m: 0.94(CI 0.89-0.97) 
18m: 0.94(CI 0.88-0.97) 
Lower level facilities 
6m: 0.94(CI 0.89-0.96) 





Viral load suppression (%) 
Higher level facilities 
6m: 70.4(CI 66.4-74.2) 
12m:70.5(CI 64.9-75.8) 
18m:71.6(CI 60.5-81.1) 
District level facilities 
6m: 61.2(CI 51.1-70.6) 
12m:90.9(CI 80.0-96.9) 
18m:90.3(CI 74.2-97.9) 
Lower level facilities 





Higher level facilities 
6m: 59.1(CI 54.9-63.1) 
12m:73.3(CI 67.9-78.3) 
18m: 100 
District level facilities 
6m: 65.5(CI 55.8-74.3) 
12m:74.2(CI 60.9-84.7) 
18m:90.3(CI 74.2-97.9) 
Lower level facilities 





et al (2012) 
48 months 
Higher level facility 
Total: 42 over 1,016CY 
Crude mortality rate: 
4.1/100CY (CI 3.0-5.6). 
Lower level facilities 
No mortality was reported 
among 158 children 
followed up at lower health 
facilities through the 
median months of 29 (IQR 
20-40) 
NR 
Lower level facility Vs 
higher level facilities. 
none of the patients 
was loss to follow-up 
regardless of the level 
of health care. 
Viral load suppression (%)Higher 
level facility 
12m: 1/37(2.7%) 
24m: 1/35 (2.85%) 
36m: 1/35 (2.85%) 
48m: 0/27 (0%) 
Lower level facilities 
12m: 0/20(0%) 
24m: 0/16 (0%) 
36m: 0/18 (0%) 
48m: 1/18 (5.6%) 
Median CD4% change 
Higher level facility 
CD4% at time of transfer: 6% (IQR2-
13) 
Lower level facilities 
CD4% at time of transfer: 5% (IQR 2-
11) 
Median difference between HP Vs OC 




Higher level facility in 
73- 93% of patients 
93 - 100% 
 
Lower level facilities in 
83-95% of patients 
95 - 100% 










All measures during follow-up (473) 
VL > 400 copies/mL was likely 
detectable in children in lower health 
facilities compared to children in higher 
level facility (17% Vs 8%, p=0.002). 
 
Mean difference between last visit and 6 
months after transfer (mean difference 
was -1.4, (-4.5, 1.7𝐶𝐼 𝑝 = 0.37) among 
HP Vs OC children 
 
 
Higher level facility a 
79.3% 
Lower level facilities 
69.2% 








3months of transfer from 
higher health facility: 1/153 
(0.65%) 
NR NR 
96% of children down referred with VL 
suppressed remained suppressed at the 
last study evaluation. 
77% of children down referred with 
subtherapeutic response to ART 



















Loss to follow-up Virological Immunological (CD4) Adherence 




Odds of mortality between 
patients successfully 




Traced transferred out 
patients 
22 of 634 alive and on ART 
(4%) 
Not transferred out 
120 of 3370 ART (3.5%) 
NR NR NR 




Odds of mortality between 
patients follow up at lower 
health facilities Vs higher 
facility 
aOR 0.19(CI 0.15-0.25) 
 
Cumulative probability of 
LTFU between patients 
follow up at lower level 
facilities Vs higher level 
facility 















Lower health facilities Vs 
higher health facility 





Lower health facilities Vs 
higher health facility. 
aHR 0.3(CI 0.2-0.6) 
 
Viral rebound (cumulative 
probability) 
Lower health facilities Vs 
higher health facility. 
aHR 0.6(CI 0.4-0.9) 
 
Change in CD4 count 
Higher level facility 
Median increase in CD4 count: 
59 𝑐𝑒𝑙𝑙𝑠/𝑚𝑚3 (IQR -12 - 146) 
Lower level facilities 
Median increase in CD4 count: 





Long et al (2011) 12 months 
 
Mortality (%) 
Higher level facility 
25/2136 (1.2%) 
Lower health facilities 
0/712 (0%) 
 
Relative risk (Death & 
LTFU) of patients in lower 
facilities Vs higher health 
facility. 
RR 0.27(CI 0.15-0.49) 
 
LTFU (%) 
Higher level facility 
108/2136 (5.1%) 







Connor et al (2011) 
Mean follow-up time 
of 0.57 years 
NR NR 
LTFU (%) 
4.11% of 3361 patients 
NR NR NR 
NR: Not reported, CI: Confidence interval, IQR: Interquartile range, VL: viral load, Viral Rebound: > 1000 copies/ml after suppression, OR: Odd ratio, aOR: adjusted odd ratio, HR: hazard ratio, aHR: 
adjusted hazard ratio, LTFU: Loss to follow-up
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Loss to follow-up Virological Immunological (CD4) Adherence 







time within a group 






















et al (2013) 
8821 patient years 
Mortality and LTFU 
Higher level facility 
116.8 per 1000py 
Lower level facility 
29.8 per 1000py 
 
Overall cumulative 
probability of mortality 
and LTFU between lower 
and higher level facilities. 




Overall cumulative probability 
of virologic rebound between 
lower and higher level facilities. 




Adherence (%) n= 502 
97% 










probability of mortality 
and LTFU between lower 
and higher level facilities. 





Cumulative probability of 
LTFU between patients 
follow up at lower health 
facilities Vs higher facility 
aHR 1.36(CI 1.09-1.69) 
 
Cumulative probability of Viral 
load failure between lower level 
facilities and higher level 
facility. 









6 Outcomes  
Clinical outcomes (successful transfer, mortality, loss to care and loss to follow-up (LTFU)), as 
well as immunological and virological, outcomes, were reviewed (Tables 5-7). 
 
6.1 Successful transfer  
In keeping with the focus of this study  “successfully transferred”  are patients’ that successfully 
re-engaged with HIV care at transferred out lower level facilities during a specified time interval. 
The transfer from one facility to another is potentially a period of high risk of LTFU when patients 
may be unable to re-engage in care at a facility that is not familiar to them. Successful transfer in 
this context is methodologically the opposite of loss to programme at the time of transfer. In 
evaluating the effectiveness of the decentralization model of HIV care in LMICs, a better 
understanding of patients transfer pattern is critical as the effective transfer of patients through the 
HIV continuum of care is central to the success of decentralized care models. 
 
While some studies report on LTFU overall and outcomes after transfer out, only seven adult 
studies and no paediatric studies reported on successful transfer itself, due to the challenges in 
tracking transferring patient outcomes in LMICs (43). The proportion of patients that successfully 
transferred to a referral site ranged from 78% to 96% (21, 24). A median time to successful transfer 
of 1.3 months was reported in a Malawian study. Since medication is dispensed monthly, this 
means that a substantial number of patients may have interrupted treatment for more than 2 weeks 
before presenting at the transfer out site.  
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Furthermore, a Kenyan study found that patients formally transferred to lower level facilities are 
more likely to re-engage with HIV care at lower level facilities than those not formally transferred. 
However, even among patients successfully transferring, about 40% could have experienced a 
treatment interruption defined as a treatment gap of greater than 14 days (24). The tracking 
methods adopted by these studies were mostly resource intensive and might be expensive to 
replicate routinely in a large decentralization programmes. None of the seven studies used an 
electronic record system to track the movement of transferring patients (Table 7). 
Table 7: Successful transfer outcome 
Author Proportion of 
successful transfer. 
Median time to 
successful transfer 
Tracking Method 
 Hickey et al (2016) 96% of 23 Cumulative incidence 
of successful transfer 
at 3 months after last 
appointment at higher 
level facility 91% 
(95% CI 69-98%). 
Chart abstraction. 
Colasanti et al (2016) (
436
458
) = 95% NR Self-reported questionnaire. 
Ghate et al (2014) (
123
158
) = 78% NR Telephonic calls to transferred out 
patients or sites. 
 Yu et al (2008) (
737
805
) = 92% 1.3 months Telephonic calls to transferred- 
out sites + Active follow up 
Connor et al (2011) (
3208
3361
) = 96% NR Active patients recording tracing 
+ Active follow up + Telephonic
calls to patients. 
 Searle et al (2010) (
1624
2071
) = 78% NR File Audit. 
Cloete et al (2014) 82% of 3913 NR Self-reported + validation through 
survey. 




Ten studies reported mortality or survival outcomes, most commonly as cumulative probabilities 
using a product limit estimator.  
 
Nonetheless, the Thailand paediatric study presented a crude death rate of 4.1 per 100 child years 
in children managed at higher level facility compared to no mortality reported in those transferred 
out to lower level facilities. The authors explained the 100% survival of children transferred out 
to lower level facilities by the fact that these children were stabilized on ART with at least 6 months 
follow-up time at higher level facility before transfer out occurred (10). Furthermore, the 
Tygerberg children’s hospital study reported 1 death among 153 children transferred out to lower 
level facilities within 3 months of transfer out (17). This result could also be due to the fact that 
children transferred out were stable on ART because 80% had a suppressed viral load at the time 
of transfer out for continuation of HIV care (17). 
 
A number of studies compared mortality in those treated at different level of health care or in those 
transferred out to lower level facilities compared to those remaining at higher level facilities. In 
children, Bock et al (2008) reported a reduced mortality risk in children managed at level 1 health 
care facilities (PHC) compared to level 2 and 3 health care facilities at  6 months (IRR=0.33 
p<0.001), at 12 months (IRR=0.39 p<0.003) and at 18 months (IRR=0.38 p<0.018). This study 
did not present the confidence intervals for effect size estimates (13).  
 
Almost all adult studies showed lower mortality among patients transferred out to lower level 
facilities compared to those remaining at high level facilities with estimates of the effect ranging 
from aHR 0.2; (CI 0.04-0.80) at 12 months on ART (18) to aHR 1.51; (CI 0.90-2.55) at 60 months 
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on ART (22). The latter study is the only one to show evidence of an increased risk of mortality in 
patients transferred out to lower level facilities compared to those managed at higher level facility, 
however this was not significant.  
 
While it is possible that even in adjusted analyses there is residual confounding with patients that 
are clinically well-being preferentially transferred to lower level facilities, these results suggest at 
a minimum that mortality in stable patients on ART is no worse when transferred to lower level 
facilities versus remaining at higher level facilities.  
 
6.3 Loss to follow-up 
Despite the WHO definition of LTFU or drop as > 90 days from missed clinical or drug pickup 
appointment without any follow-up contact (44), disparate definitions of LTFU were used by 
researchers to assess this outcome. Benjamin et al (2011) suggested a universal definition of  LTFU 
as no clinic visit 180 days after the last visit to clinic and before database closure (45). However, 
this is a “retrospective” definition of LTFU mainly used to assess the likely completeness of 
mortality outcomes. In contrast, the WHO definition is prospective and allows focuses on all gaps 
in care (46).  
 
Bock et al (2008) reported less attrition (describe as patients who died plus those LTFU) in children 
managed at lower levels facilities of Western Cape Province, SA through 18 months of follow-up 
(13). Remarkably, the Thailand paediatric study showed that no child was loss to care at both lower 
and higher level facilities through 24 months of follow-up (10). All adult studies that reported 
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LTFU showed less LTFU in patients managed at lower level facilities compared to those managed 
at higher level facilities (18, 19, 22, 27). 
In summary, these results suggest that the decentralization of patients to lower level facilities 
reduces loss to follow-up, possibly because patients are being seen at facilities that are closer to 
their homes with fewer barriers to access the facility. 
6.4 Adherence Outcomes 
Patients’ adherence to treatment was described in two adults and two paediatric studies. Optimal 
adherence was consistently defined as at least 95% pills or liquid medications taken based on pill 
counts or volume measurement. In Thailand, children had similar and high adherence of 100% 
irrespective of the level of facilities at which they were managed through 48 months of follow-up 
(10). In contrast, the Zambian paediatric study reported better adherence in children managed at 
higher level facilities compared to those managed at lower level facilities. However, the median 
percentage of optimal adherence before and after transfer was not different for children transferred 
out, 75% (IQR:50-100) and 75% (IQR:44-100) respectively. Nevertheless, this study also reported 
that 99% of 77 caregivers agreed that lower level facilities were closer to their homes compared 
to ART initiation sites (29). Both adult studies of community decentralized models of ART care 
reported similar and good adherence measured by self-report (14, 15).  
6.5 Virological Outcomes. 
Virological outcomes were measured in seven studies including all studies in children (10, 13, 17, 
29) which is encouraging considering that viral load monitoring is not always routinely available
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in LMICs. This is also important because this outcome could serve as a proxy measurement for 
patients’ adherence to treatment.   
Bock et al (2008), found that viral load suppression was highest at level 1 (lower level) facilities 
compared to level 3 facilities at 12 and 18 months on ART (13). Transfer out to lower level 
facilities of stable children might partly explain the better viral load outcome of patients in lower 
level facilities. 
In contrast, there was a higher proportion of viral load suppression in Thailand’s children managed 
at higher level facilities compared to those transferred out to lower level facilities at 12, 24 and 36 
months respectively. However, the number of children with viral load results at each interval was 
low and children transferred out to lower level facilities had a relatively smaller proportion with 
viral load data (10). Similarly, the Zambian paediatric study also reported that viral load (> 400 
copies/mL) was more likely in children managed at lower level facilities compared to those 
managed at a higher level facility (29). It is possible that at lower level facilities children who were 
less well were more likely to undergo viral load testing, accounting for lower viral suppression. 
In contrast, among children transferred out of Tygerberg children’s hospital, who had suppressed 
viral load at the time of transfer out (80% of 153), virologic suppression was maintained in 96% 
after a median follow-up of 2 years. In addition, 77% of the 26 children not virologically 
suppressed at transfer achieved virologic suppression after 6 months of support and treatment at 
lower level facilities.  
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In adult studies,  Brennan et al (2011) reported an increased probability of viral rebound (> 400 
copies/mL)  in patients managed at a higher level facility compared to those managed at lower 
level facilities at 12 months follow-up (18). Similarly, a community decentralized ART study 
reported a decreased cumulative probability of viral rebound in patients managed in the community 
compared those managed at the ART initiation facility (15). Furthermore,  Grimsrud et al (2014) 
found that patients managed at lower level facilities are less likely to experience virologic failure 
compared to higher level facilities at 60 months of follow-up (22). Nonetheless, in the SA 
adherence club study patients in a community adherence club are less likely to experience virologic 
rebound compared to those not in adherence club (15). 
These results put together suggests that patients’ virologic trajectories continued to improve at 
lower level facilities or at the community. This also underscores the fact transferring patients to 
lower level facilities closer to their home can also help improve their adherence to treatment. 
 
6.6 Immunological outcome 
Only three paediatric studies and one adult study reported on CD4 outcomes. Bock et al (2008) 
reported a comparable increase in the proportion of children with CD4% > 20% in children 
managed at the level 1, 2 and 3 facilities through 18 months on ART, using programme-level data 
(13). Similarly, the Thailand and Zambian paediatric studies showed that changes in CD4% in 
children transferring to lower level facilities were comparable to children remaining at higher level 




In contrast, the only adult study that reported the immunological outcome of patients reported a 
better median increase in CD4 count in patients managed at a higher level facility compared to 
those managed at lower level facilities at 12 months of follow-up (18). 
 
7 Determinants of patients’ outcome 
The predictors of primary outcomes that were assessed were at ART initiation/ at time of transfer 
out characteristics of clinical, immunological, virological, disease severity, treatment regimen and 
follow-up time, as well as socio-demographic variables of age, sex, gender, education level, 
employment status, levels of health care, orphan status, transfer pattern, attributable stigma, 
distance from health facility and marital status (Tables 8-9c). 
 
7.1 Determinants of successful transfer outcome 
Of note, four adult studies assessed the predictors of successful transfer/relinkage to care (21, 24-
26). These studies assessed both patient-level characteristics and structural-level characteristics 
which include HIV care programme characteristics.  
 
In India, patients’ that were either single, divorced or widowed were more likely to re-engage with 
care at transfer out facilities in univariate regression analysis. However, the reported odds ratio 
was imprecise with large confidence intervals due to the small sample size of the study and an 
adjusted analysis was not presented  (21).  
 
An SA study found that patients who were not pleased with the transfer out facilities were less 
likely to re-engage with care (25). Similarly, attributable stigma was identified as a predictor of 
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patients’ failure to re-engage with care in Kenya (24). Other patient-level characteristics identified 
to be associated with patients’ reengagement with HIV care in SA were better adherence score and 
shorter duration of ART before transfer (25).  
At the programme level,  “official transfer” was identified as a significant predictor of patients’ 
reengagement with care in Kenya (24). Cloete et al (2014) described the structural factors 
associated with not being found at transfer out facilities. For every 1 kilometre that the transfer out 
facility was from the higher level facility there was an increased risk of patients not being found 
in care. This highlights the fact that transferring patients to a site closer to their home might be 
effective in keeping patients’ in care (26). In addition, patients’ on second-line ART transferred 
out to lower level facilities were less likely to transfer successfully (26).  
7.2 Determinants of mortality outcome. 
Predictors of mortality were presented in two paediatric studies. Lower level facilities were 
associated with reduced mortality through 18 months follow-up in an SA paediatric study (13). 
Furthermore, In Thailand, children severely underweight and those with severe immune 
suppression (CD4 < 5%) were found to be associated with increased mortality in multivariate 
analysis (10).  
Of the seven studies that described the predictors of their outcomes in adult studies, five of these 
studies reported the predictors of mortality (18, 19, 22, 27, 28). All of the five studies reported 
lower level facilities as an independent predictor of reduced risk of mortality in univariate 
regression analyses. Lower level facilities and community adherence clubs remained associated 
with reduced risk of mortality in multivariate regression analyses presented by four studies (15, 
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18, 27, 28). In addition, the predictors of LTFU were assessed in five adult studies (15, 18, 19, 22, 
27). Three of these studies reported lower level facilities and community adherence clubs as 
associated with reduced risk of LTFU (15, 18, 27).  
 
7.3 Determinants of viral load and adherence outcome. 
The Zambian paediatric study, assessed the predictors of viral load suppression using a generalized 
estimating equation model with levels of health care facility as a time dependent covariate (29). 
Patients managed at lower level facilities had increased risk of detectable viral load defined as 
>400 copies mL, >1000 copies/mL and >10000 copies/mL through 3 years of follow-up (29). 
 
Furthermore, patients’ characteristics associated with viral load rebound were assessed in five 
studies, which included one paediatric study (17-19, 22). The results of these analyses suggest that 
lower level facilities or community ART club are associated with reduced risk of viral load 
rebound in all but one study. The Tygerberg children’s hospital study reported that children 
initiated on ART at PHC are less likely to experience viral rebound compare to patients transferred 
out from higher level health care facility (17). This result raised the question about the level of 
adherence of patients transferred out from higher level facilities and suggests that patients 
transferred out may experience an interruption in treatment during the transition period.  
 
The predictors of adherence were assessed by the Zambian paediatric study. The result suggests 
that children transferred out to lower level facilities are less likely to achieve optimal adherence 
defined as the > 95% clinic visits. However, this result was not significantly different from children 
managed at higher level facility (29). 
 
38 








Mortality outcome Loss to follow-up Virological outcome Adherence 





Level 2 and 3 hospitals 
PHC: 
6m: aIRR = 0.33 (p<0.001) 
12m: aIRR = 0.39 (p=0.003) 















< 5% at ART initiation: 



















Reference: Higher level facility 
Lower level facilities: 






Reference: Higher level 
facility 














Reference: Down referred 
patients 




Also every 1 log increase in 
baseline VL, the odds of 







NR: Not reported, CI: Confidence interval, IQR: Interquartile range, VL: viral load, PHC: Primary Health Care, ART: Antiretroviral therapy, aHR: adjusted hazard ratio, aIRR: adjusted incidence rate 
ratio, aOR: adjusted Odds ratio.
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Mortality outcome Loss to follow-up Virological Adherence 



















Reference: Higher level 
facility 




Reference: Higher level 
facility 



























Reference: ≥ 50 years 






viral load rebound 
Reference: Not down-referred 
Down-referred: aRR:0.6(CI 0.4-
0.9) 
Reference: ≥ 50 years 



























in care and responding to 
treatment (undetectable viral 
load/sufficient change in CD4 
 






















Mortality outcome Loss to follow-up Virological Adherence 
Luque-Fernandez 






loss to care (death/LTFU) 
 











Reference: Not in adherence 
club 





Adherence club enrolment 




Ghate et al (2014) Transferred in 
Transferred in 
Reference: Living with 
partner 
























Reference: Higher level 
facility 























Every 1KM from clinic: 
aRR:1.07(CI 1.02-1.13) 
 
Patients on 2nd line regimen 





NR NR NR NR 
NR: Not reported, CI: Confidence interval, IQR: Interquartile range, ART: Antiretroviral therapy, aHR: adjusted hazard ratio, OR: Odds ratio, HR: hazard ratio, aRR: adjusted risk ratio, KM: Kilometres
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Mortality outcome Loss to follow-up Virological Adherence 
Colasanti et al 
(2016) 
Retention in care 
 
Patient sentiment towards 
attending the clinic 
 
Reference: Not pleased with 
the clinic 




Reference: < median score 
≥ median score: 
aOR 3.89(CI 1.21-12.48) 
 
Duration of ART 
Reference: Short duration 
Longer duration: 












Hickey et al (2014) Relinking to care 
Transfer status 
Reference: Without official 
transfer 




1-point increase in 
perceived stigma in the 
community: 










NR: Not reported, CI: Confidence interval, IQR:  ART: Antiretroviral therapy, aHR: adjusted hazard ratio, aOR: adjusted Odds ratio
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8 Summary, interpretation and needs for further research 
Despite an extensive search, there were only fifteen studies that met the pre-specified inclusion 
and exclusion criteria for this review with two additional studies (21, 28) identified from the 
bibliography search of these studies. Only four of the studies were done specifically in children.   
The primary focus of our study, namely successful transfer, was sparsely reported in the studies 
included. Indeed, no paediatric study aimed to assess this outcome, which is not surprising 
because conventional survival analyses censor patients at transfer out date (47). Seven adult 
studies reported on this outcome, but the review highlights the resource intensive methods 
required to be able to do this. Most studies showed a high proportion of patients successfully 
transferring and an encouragingly short median time to successful transfer of 1.3 months in 
Malawi underscoring the effectiveness and feasibility of decentralizing HIV care to lower level 
facilities in LMICs (28). Nevertheless, some studies reported delays in time to successful 
transfer which could result in treatment interruptions.  
None of the seven studies that reported on the transfer status of patients’ used a laboratory or 
an electronic monitoring system to monitor the movements of their patients’ transferring 
between ART sites. These studies tracked their transferring patient’s through resource-
intensive methods, which might be logistically challenging for a large decentralization 
programme and cannot be implemented as part of routine programme evaluation. Nonetheless, 
an SA paediatric study extracted missing laboratory tests of children transferred out from 
Tygerberg children’s hospital using SA NHLS data (17), suggesting that the approach of our 
study is feasible and that the SA NHLS could potentially provide a reliable and real-time 
efficient method for tracking the outcomes of transferring patients. 
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All four paediatric studies included in this review suggest that children transferred out to lower 
level facilities had comparable viral load and CD4 outcomes with those managed at higher 
level facilities, and highlights that lower level facilities have sufficient capacity to manage 
HIV-infected children.  
Results about the predictors of patients’ reengagement with HIV care after transfer highlight 
the importance of conducting context-specific research to improve decentralized models of 
HIV care. Evidence from the literature reviewed indicates that programmes characteristics, 
patients’ characteristics and structural factors are major determinants of patients’ reengagement 
with HIV care. Therefore, the predictors of successful transfer are most likely a function of an 
interplay between these factors which are important for informing programmatic decision.   
8.1 Summary of study quality and validity 
As the studies included in this review differed by age group, decentralization model for ART 
services (partial and community decentralization model), follow-up time, immunological and 
virological thresholds, sample size and setting, comparability of results between studies is 
challenging. The ideal good quality study would be done prospectively, have adequate sample 
size backed up by sample size calculation to assess patients’ transfer, immunological, 
virological outcomes and ensure comparable characteristics between patients transferred out or 
remaining in care at the higher level facility.   
None of the studies reviewed fulfilled these criteria. The retrospective design of the studies 
reviewed is of major concern with regards to the quality of data and the inherent flaws of 
retrospective studies. Of note, survival bias is a major threat to internal validity in the studies 
reviewed because most of the studies included in this review transfer out patients based on the 
improvement in the clinical status thereby leaving sicker patients to be managed at higher level 
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health care facilities. This ultimately favours the intervention group (transferred out patients) 
and might explain the better outcomes reported in patients’ transferred out to lower level 
facilities for continuation of HIV care. Furthermore, since the studies reviewed are all 
observational studies the non-randomization of patients’ to transfer out/not transfer out group 
is also a concern with regards to selection bias. Another source of threats to internal validity in 
the studies reviewed were how missing data were treated and unmeasured confounders, which 
were sparsely handled in most of the studies included in this review. 
In addition, the retention estimates among those who successfully transfer are important to 
report, but they are biased. Patients that successfully transfer have already demonstrated 
retention by successfully transferring, and so are likely to have better long term retention. Thus 
the outcomes of these patients do not represent overall retention of all patients transferring out 
and are not directly comparable with patients not transferred from their primary care site. 
Nevertheless, Brennan et al (2011), Long et al (2011) and Hansudewechakul et al (2012) 
studies used advanced methodological approaches to improve the internal validity of their 
studies (10, 18, 19).   
8.2 Questions that emerge and could form the basis for further research 
The findings from the studies reviewed shows that decentralized models of ART care have 
been used effectively for optimizing the delivery of ART care for patients in LMICs with weak 
health systems and a high burden of HIV/AIDS, with satisfactory clinical and laboratory 
outcomes. Nevertheless, results in children remain very limited with no studies reporting on 
the outcome of successful transfer in children. This review highlights the importance of 
understanding patient-level, program-level and structural factors impacting transfer outcomes 
in different contexts in order to optimize transfer success and the outcomes of decentralized 
care. 
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Decentralization is likely to become widespread as the promising results from existing studies 
have spurred the International AIDS Society to commit to a two year differentiated models of 
ART delivery project aimed at supporting LMICs to adopt decentralization of HIV care and 
task-shifting among other strategies. While this project aims to expand coverage of ART 
services in LMICs, it will also come with challenges of finding an efficient way for tracking 
the movement of patients’ between treatment sites considering the poor record systems and 
constrained health systems in LMICs. This review highlights the challenges of tracking patients 
and methods used by studies that reported on the successful transfer outcome in their patients, 
and there is a clear need to explore the feasibility of using electronic systems and laboratory 
data to track patient outcomes at scale. 
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Abstract 
Background. Decentralisation of paediatric HIV care in resource-limited settings has 
expanded ART access. However, there is limited data on outcomes of children transferred from 
higher to lower level health facilities.  
Objectives. To describe the outcomes of children who initiated ART at Red Cross War 
Memorial Children’s Hospital (RCWMCH), a tertiary paediatric facility in the Western Cape 
Province (WCP) of South Africa, and were transferred to lower level facilities within the WCP. 
Method. This was a retrospective study of ART-naïve HIV-infected children <16 years old 
who started ART at RCWMCH from December 31, 2007 to January 1, 2012. We linked 
RCWMCH cohort data to National Health Laboratory service data (NHLS) data using the 
unique identifier. Successful transfer was defined in two ways: a laboratory test performed by 
a lower level health facility (i) ≤18 months or (ii) ≤48 months after transfer date. 
Results. The median age at ART initiation of 1127 children included was 5.6 months 
(interquartile range [IQR] 3.1-19.9); at ART initiation 85% had WHO stage III/IV disease and 
57% were immunosuppressed. Of 725 (64%) children who were transferred, 69% (496) and 
76% (541) successfully transferred within 18 and 48 months respectively. Median time to 
successful transfer was 5.6 months (IQR 3.8-9.1). In patients who successfully transferred, 
median (IQR) CD4% increased between transfer and first visit post-transfer (25.1% (17.3-
33.8%) vs 30.2% (22.9-36.6%), p-value <0.001) and the proportion of children with HIV RNA 
<400 copies/mL increased from 55.9% to 81.4% (p-value<0.001). Children with the transfer 
site recorded in the RCWMCH database and those transferred out before 2010 were more likely 
to successfully transfer (adjusted odds ratio (aOR):7.99; 95% CI:2.3-28.5 and aOR:5.21; 95% 
CI:1.5-18.4 respectively). 




The burden of paediatric human immunodeficiency virus (HIV) is disproportionately 
distributed with sub-Saharan Africa accounting for more than 80% of the global burden of 
paediatric HIV. Despite the progress seen with HIV-infected patients’ access to antiretroviral 
therapy (ART), only 49% of about 1.8 million children living HIV have access to ART.[1]  
To guide global action on paediatric HIV care, the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) has called for 90-90-90 targets – to identify 90% of HIV-infected 
children, maintain 90% of those identified on treatment and achieve 90% viral load suppression 
among those on treatment.[2] Building on this, decentralisation of HIV care was recommended 
by the World Health Organisation (WHO) to address the human resources shortage and long-
term retention challenges of patients in HIV care. These treatment models involve shifting HIV 
care services to lower level facilities, thereby encouraging patients’ retention in care and 
improving access of patients to care. [3, 4] In the same vein, decentralisation of paediatric HIV 
care aims to strengthen the paediatric HIV continuum of care.[4, 5]  
Across LMICs, decentralised HIV care models are increasingly being used to remove 
children’s barriers to accessing paediatric HIV services.[4, 6] The Western Cape Province 
(WCP) of South Africa (SA) adopted a decentralised model of paediatric HIV care soon after 
the start of ART roll-out in 2004, and the proportion of children receiving ART at the 3 tertiary 
health care facilities in WCP declined from 78.4% to 38% between March 2004 and September 
2006.[7] 
Red Cross War Memorial Children’s Hospital (RCWMCH), a WCP tertiary level health facility 
initiates infants or sick children on ART. These children are transferred to lower level facilities 
within the WCP for continuation of HIV care within the decentralised model once they are 
stable on ART. However, there is no published information on whether these children reached 
transfer out sites and how they fare if they successfully transfer. This study, therefore, aims to 
investigate the outcomes of children transferred out from RCWMCH using RCWMCH data 
linkage to the South African National Health Laboratory Service data (NHLS). 
Methods 
Study design and population 
We conducted a retrospective analysis of children initiated on ART at RCWMCH and 
transferred to lower level health facilities for continuation of HIV care from between December 
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31, 2007 and January 1, 2012. (Figure 1). Routine clinical follow-up data were collected for 
this cohort of children as part of standard treatment and monitoring of HIV care and stored in 
an electronic database. Since 2007, a single unique patient identifier is used across all health 
services in WCP. The NHLS conducts all WCP public sector laboratory tests. Provincial 
approval was obtained to link RCWMCH data to WCP data and this linkage was performed by 
province staff with permission to access identified data. 
The analysis included NHLS data on CD4 and viral load results from all WCP facilities 
providing HIV care for children during the study period. Children were managed using the 
South Africa (SA) paediatric ART guidelines during the study period which are adapted from 
the WHO paediatric ART guidelines [8] According to the RCWMCH ART guidelines, children 
should be transferred out to lower level health facilities once they are stable on ART if feasible 
(i.e. there is a suitable clinic close to patient’s home and caregiver is agreeable to transfer). and 
provided with a referral sheet containing the name of the referral site, next appointment date at 
referral site, medical summary, most recent laboratory test results, and, if already on ART, the 
current drug regimen. This referral sheet was presented at the referral facility upon arrival for 
the continuation of HIV care.[9] Routine laboratory monitoring in the WCP included CD4 
absolute and percent as well as viral load at initiation, after 6 months, after 1 year and 
annually.[9] A laboratory test performed closest to the transfer out date defined as at least 12 
months of ART care at RCWMCH was used to identify patients’ characteristics at transfer. 
Children transferred out to a site outside the WCP were excluded from the analysis (Figure 1). 
Ethical approval for this analysis was obtained from the University of Cape Town Human 
Research Ethics Committee, Faculty of Health Sciences (Appendix D). 
Key cohort characteristics and outcomes 
Clinical and laboratory characteristics of children at ART start were summarised using medians 
and interquartile ranges (IQR) for continuous variables and proportions for categorical 
variables.  Age at ART initiation was categorised as < 1 year, 1-1.9 years, 2-4.9 years, 5-9.9 
years and ≥ 10 years due to faster disease progression in infants and young children, and 
different adherence and retention expected in those >10 years. Weight for age z-score (WAZ), 
height for age z-score (HAZ) and body mass index for age z-score (BAZ) were categorised 
using WHO 2006 standards as <-3, -3 to -2 and >-2. Children were considered severely 
immunosuppressed if the lowest of the CD4 absolute cell count or percentage met the WHO 
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immunosuppression classification criteria for their age.[10] Viral load suppression was defined 
as HIV-RNA < 400 copies/ml. 
The primary outcome of successful transfer was defined in two ways: a laboratory test 
performed by a lower level facility (i) ≤18 months or (ii) ≤48 months after the transfer date. 
The first interval corresponds to South African national guideline recommendations for annual 
CD4/viral load monitoring; the second aimed to capture all children retained in care even if 
monitoring was not carried out as frequently as required by guidelines.  
In children that transferred successfully, their change in immunological and virological 
outcomes at transfer out and post-transfer was described. CD4 and viral load at transfer were 
the values closest to the transfer out date within a window of 12 months prior to transfer out 
from RCWMCH, while post-transfer values were the results of the first CD4/viral load test 
after transfer. Also, the predictors of successful transfer were assessed, while the feasibility of 
using NHLS for tracking the movement of children between HIV treatment sites was 
demonstrated. 
Statistical methods 
We compared successful transfer of children from three broad categories; (i) Children whose 
transfer out site was recorded in the RCWMCH database (ii) Children with no recorded transfer 
out site but recorded residential information (iii) Children with neither recorded transfer out 
site nor residential information. Logistic regression was used to assess the effect of these 
categories on transfer outcomes after adjusting for other predictors of successful transfer. No 
cut-off for p-value was used to define statistical significance to include the variables into the 
logistic multivariate analysis as all p-values for all the analysis was reported exactly.[11] The 
median time to successful transfer was also reported. 
In patients who successfully transferred, we compared characteristics of patients at transfer out 
and first visit post-transfer, using Wilcoxon Signed Rank Test for paired samples and chi-
squared test/Fishers-exact test for continuous and categorical variables respectively. This 
analysis was restricted to patients with measurements recorded both at transfer out and at first 
visit post-transfer date. All statistical analysis was done using STATA 14.1 version.[12] 
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Figure 1: Flow Chart of RCWMCH HIV-Infected Children in the HIV Care Network, 2007-2012 
 
*: Children were excluded from analysis because they were transferred to sites outside Western Cape Province. 
+: A sub-analysis including these children was conducted.
Children transferred out to lower level of health 
facilities within Western Cape Province during 
the study period n= 725 
Children not transferred out during 
the study period n= 402 
Children initiated on ART at RCWMCH during the study period n 
= 1173 
Successful transfer within 18 months 
Children with ≥ 1 laboratory record at transfer 
facility within 18 months of transfer out date 
N=496 (68%) 
Successful transfer 18-48 months after transfer 
out 
Children with ≥ 1 laboratory record at 
transfer facility between 18-48 months after 
transfer out date 
N=45 (6%) 
Children with no records of successful transfer n=184 
(25%). 
Note: a subset of 20 (11%) of these children returned to 







Cohort and patient characteristics at ART start 
The median age at ART initiation of 1127 children included was 5.6 months (IQR 3.1-19.9 
months) with median follow-up at RCWMCH of 8.5 months (IQR 1.3-22.9). During this 
period, 725 (64%) children who initiated ART at RCWMCH were transferred out to lower 
level facilities within the WCP for continuation of HIV care (Figure 1). The characteristics at 
ART start of children transferred out to lower level facilities and those managed only at 
RCWMCH were similar, except that children transferred out had higher median CD4 count of 
471 (IQR 195-1044) vs 385 (IQR 131-960) (p-value=0.045) (Table 1). At ART initiation, most 
of the children had advanced disease; approximately 85% of children were classified as WHO 
clinical stage III/IV, 57% were immunosuppressed and median log10 viral load (copies/ml) was 
5.9 log10 copies/ml (IQR 5.1-6.5). Approximately 71% of children were either moderately or 
severely underweight (Table 1).  
Table 1. Characteristics of RCWMCH patients transferred from 31st December 2007 – 
1st January 2012 at ART start 
Characteristics at 
ART initiation 
Entire cohort that 
initiated ART (n= 
1,127) 
Patients transferred 
to lower level health 





𝐩 − 𝐯𝐚𝐥𝐮𝐞 ∗ 










Age, months  
Median (IQR) 5.6 (3.1 to 19.9) 5.1 (3.0 to 19.8) 6.2 (3.2 to 19.9)  0.44 
WHO HIV staging 3 












9 (2.24) 0.48 
CD4 count  
Median (IQR) 436.5 (175 to 999) 471 (195 to 1044) 385 (131 to 960) 0.05 
8 
Missing, n (%) 325 (28.84) 218(30.07) 107(26.49) 
CD4 %  
Median (IQR) 
Missing, n (%) 
17 (9.8 to 25.1) 
333(29.55) 
17.2 (10 to 25) 
223(30.76) 
16.6 (9.45 to 25.6) 
110(27.23)  0.38 
Log viral load 
(copies/ml)  
Median (IQR) 
Missing, n (%) 
5.88 (5.14 to 6.48) 
398(35.31) 
5.88 (5.15 to 6.46) 
260(35.86) 
5.88 (4.98 to 6.48) 
138(34.16) 
 0.73 
WAZ score  
Median (IQR) -2.44 (-3.57 to -1.37) -2.37 (-3.43 to -1.39) -2.57 (-3.87 to -1.29)  0.16
WAZ score 
category, n (%) 
<-3 SD 
















HAZ score  
Median (IQR) -2.29 (-3.47 to -1.28) -2.28 ( -3.41 to -1.26) -2.41 (-3.64 to -1.49) 0.17
HAZ score category, 
n (%) 
<-3 SD 

















Median (IQR) -1.65(-3.2 to   -0.58) -1.64( -3.15 to -0.59) -1.65 (-3.43 to -0.43) 0.79
BAZ score category, 
n (%) 
<-3 SD 













































NB: The p.value compares the characteristics of patients that transferred to lower level facilities 
compared those to those not transferred during the study period.  
Successful transfer outcome 
The proportion of patients who successfully transferred was 76% (541/725 children) within 48 
months of the transfer out date, with 92% of these (496/541) successfully transferring within 
18 months of the transfer out date. A total of 68% of all children, therefore, achieved successful 
transfer within a window of 18 months from transfer-date and this proportion did not differ 
substantially in a sensitivity analysis when reducing the successful transfer window to 15 
months after transfer out date. The median time to transfer successfully was 5.4 (IQR 3.7-7.8) 
months (Table 3). Among 184 children who did not transfer successfully, 20 (11%) returned 
to RCWMCH for HIV care. Among children with recorded referral sites, 21% did not transfer 
successfully, compared to 29% among those with no referral site recorded (Figure 2). 
Predictors of successful transfer  
In multivariable analysis, children transferred out before 2010 are 5 times more likely to 
successfully transfer to lower level facilities compared to children transferred out after 2010 
(adjusted odd ratio (aOR)): 5.16, 95% CI 1.5-18.4) (Table 2). Similarly, children with recorded 
transfer out sites in the RCWMCH database were 8 times more likely to transfer successfully 
to lower level facilities compared to those with recorded residential address (aOR: 7.99; 95% 
CI:2.3-28.4) (Table 2). There were no child clinical or laboratory characteristics that predicted 
successful transfer in multivariable analysis.  





N.B:  356 (49.1%) children had recorded referral sites in the database while 358 (49.4%) had 
their residential address recorded in the database. Only 11 (1.5%) children had neither recorded 
referral site or residential address recorded in the database and 6(54.5%)of these children 



















Recorded referral site Recorded residential address
Figure 2: Transfer patterns of children 
transferred out of RCWMCH
Loss to care
Successfully transfer to a site far from  residential address
Successfully transfer to a site close to residential address
Successfully transfer to referral site
                   
11 
 
Table 2: Factors associated with successful transfer among children transferred out from 
RCWMCH from December 2007 – January 2012 
Characteristics                                                              
                                     Unadjusted Analysis                      Adjusted Analysis                                                                                                                                 
 Number of 
successful transfer 
(%) 
OR(95%CI)                  P-value     OR(95%CI)      P-value 
Gender 
(n=725) 
Female 285(52.68)             1 
 
           1 
 
Male 256(47.32) 0.96(0.69-1.34) 0.81 0.97(0.67-1.39)           0.89 
Age in years at 
transfer (n=725) 
< 1 years                                             
 
148(27.36)              1             1  
1-1.9 years 127(23.48) 1.22(0.77-1.95) 0.40 0.89(0.51-1.56) 0.66 
2-4.9 years 124(22.92) 1.19(0.75-1.91) 0.46 0.99(0.55-1.78) 0.97 
5-9.5 years 103(19.04) 1.24(0.75-2.05) 0.40 1.35(0.70-2.61) 0.37 
≥ 10 years  39(7.21) 1.00(0.51-1.95) 0.99 1.31(0.54-3.18) 0.56 




    
< 20% 175(32.35)              1             1  
≥ 20% 94(17.38) 1.01(0.62-1.65) 0.97 1.17(0.67-2.03) 0.58 
> 25% 272(50.28) 1.12(0.77-1.63) 0.56 1.18(0.74-1.88) 0.49 
Immunosuppressed at 
transfer (n=720) 
     
No 321(59.44)              1    
Yes  219(40.56) 0.85(0.61-1.19) 0.36   
Viral load suppressed 
at transfer (n=688) 
     
No 241(45.64)              1               1  
Yes  287(54.36) 1.69(1.19-2.43) 0.00 1.48(0.84-2.59) 0.18 
Follow-up 




< 6 months 194(35.86)              1              1  
≥ 6-11.9 months  125(23.11) 1.78(1.11-2.86) 0.02 1.33(0.72-2.47) 0.36 
≥ 12 months 222(41.04) 1.34(0.92-1.94) 0.12 1.04(0.53-2.05)  0.18 
Transfer site (n=714)      
Recorded resident    
address  254(47.48)              1 
 
             1 
 
Recorded transfer site 281(52.52) 1.53(1.09-2.16) 0.01 7.99(2.25-28.47) 0.00 
Year of transfer 
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From   2010 258(47.69)              1                1  
Before 2010 283(52.31) 1.39(0.99-1.95) 0.05 5.16(1.45-18.38) 0.01 
 
NB: Immunosuppressed at transfer variable was not included in the multivariate regression 
analysis because CD4% percentage variable was included in the analysis. 
 
 
Change in Children’s Immunological and Virological Status for those who remained in 
care. 
Immunological and Virological Response 
The patient-level analysis of children shows improvement in immunologic and virological 
markers among children who successfully transferred from RCWMCH (Table 3). The median 
CD4% increased between transfer out and first visit post-transfer in children that successfully 
transferred (25.1%; IQR (17.3 to 33.8) versus 30.2%; IQR (22.9 to 36.6) p-value <0.001).  In 
the same vein, median CD4 count increased between transfer out and first visit post-transfer 
(1026 cells/mm3; (IQR 563 to 1577 cells/mm3) versus 1260.5 cells/mm3; (IQR 788 to 1802 
cells/mm3) p-value<0.001) (Table 3). The proportion of children with HIV RNA < 400 
copies/mL between transfer out date and first visit post-transfer increased from 265(55.9%) to 
386(81.4%) (p-value<0.001) (Table 3).  
Children who did not successfully transfer and returned to RCWMCH 
In the sub-group analysis of 20 children transferred out who did not successfully transfer but 
returned to RCWMCH for HIV care, the median (IQR) CD4% and count were lower on return 
to RCWMCH compared to at transfer out (25.7%; (13.4 to 30.2) vs 27.8%; (19.3 to 33.2) p-
value= 0.01 and 818 cells/mm3 (598 to 1026 cells/mm3) vs 1057 cells/mm3 (707 to 1420 
cells/mm3) p-value<0.001. However, the proportion of children with viral load suppression was 
not significantly different at transfer out (11(73.3%) versus 9(60.0%) after returning to 
RCWMCH p-value = 0.24) (Table 3)
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Table 3. CD4 and Viral load in patients transferred out who successfully reached a site 
within 48 months of transfer out date 
*: The statistics presented in this section of the table are for the 20 children who failed to 
transfer successfully and returned to RCWMCH 
 
 
Characteristics Patients laboratory 
information at 
transfer 
 Patients first laboratory 






























































          Children who returned 




CD4 count (n=19) 
 
Median (IQR)
                                  
 
1057(707 to 1420) 
 
818(598 to 1026) 
 
0.0001 
CD4 % (n=19) 
Median (IQR) 
 
27.8(19.30 to 33.20) 
 
























6.09(3.57 to 12.02) 
  




Principle findings  
In this study, of the substantial number of children transferred out to lower level facilities from 
RCWMCH, more than three-quarters successfully transferred to a referral facility, with 90% 
of these children transferring within 18 months of their transfer out date from RCWMCH. The 
69% of children who have a laboratory test at the transfer site within 18 months of transfer 
out constitutes about 80-90% of children who actually transfer successfully since annual 
laboratory testing is about 80- 90% complete Therefore the proportion actually transferring 
within 18 months (in terms of clinic visits) is likely 75-80% estimate. Children’s CD4 count and 
percent increased after transfer, as did the proportion with HIV-RNA<400 copies/ml.  
Strengths and Limitations of Findings  
To our knowledge, this is one of the first paediatric studies assessing the post-transfer outcomes 
of children transferred out from higher level to lower level facilities for continuation of HIV 
care in sub-Saharan Africa. The use of NHLS linkage data to track transferred out children 
provided an easy and efficient mechanism for monitoring post-transfer outcomes, and the 
availability of a unique identifier across the health service platform in the WCP ensured the 
fidelity of linkage results. The use of NHLS data was particularly valuable for tracking patients 
where the transfer facility was not recorded or who engaged in care at a different facility from 
the one to which they were referred to.  Our study demonstrates the feasibility of using patient 
laboratory data to assess outcomes at facilities other than the treatment initiation sites both for 
programme monitoring and to improve patient care by tracking in real-time that patients reach 
their transfer site. Nevertheless, a limitation of using NHLS data is that we could only identify 
successful transfer if patients had undergone laboratory testing and so may underestimate 
actual clinical visits at the transfer site, and so, it is hard to estimate the actual proportion 
successfully transferring based on assumed completeness of laboratory monitoring. The young 
age and relative diseases severity of children included in this study are also a notable strength 
as it demonstrates that decentralisation of paediatric HIV care is possible for infants and sick 
children once they are stable on ART. 
Further limitations of the study relate to the use of routinely captured data only, so there was 
missing data on clinical and laboratory characteristics as well as incomplete documentation of 
transfer out sites. We could also not assess the effect of family socio-economic and 
15 
demographic characteristics as well as adherence on transfer outcomes as this data was not 
collected.  
Interpretation 
An increasing number of adult studies are reporting on the outcomes of patients transferring 
between ART sites in LMICs, with 78-96% of patients successfully transferring.[13-19,21] 
Although 10% of patients in a Malawian study reporting transfer were children, transfer 
outcomes for paediatric patients were not specifically reported. [17] To our knowledge, no 
paediatric study to date has reported on this outcome despite evidence that children do transfer 
between treatment sites in LMICs.[20] Our study demonstrates that transfer outcomes in children 
are comparable with adult results; 76% of children transferred out reached lower level facilities 
according to laboratory testing, and 80-85% may have actually transferred successfully as 
laboratory testing is likely only 90% complete. Only 3 studies have reported on patient’s time 
to re-engage with HIV care at lower level facilities, with a median of 1.3 months in Malawi 
and 91% of patients re-engaging in care within 3 months in Kenya. Similar result of 91% of 
patients re-engaging in care within a year of transfer out was reported in SA[14, 17, 21] Our study 
reported a longer median time to successful transfer of 5.4 months, which is likely due to using 
laboratory testing as an indicator of successful transfer rather than actual clinic visits. Although, 
>90% of children who transferred successfully did so within 18 months of the transfer date
(recommended interval for annual CD4/viral load monitoring), a small proportion only 
underwent laboratory testing at the transfer site later. This delay in laboratory testing could 
indicate that patients transferred out experienced treatment or HIV care interruptions during 
the transition period, as noted in a Kenyan adult study.[14]  
Similar to a SA study which reported that 20.8% of adults not transferring successfully had 
gone back to the treatment initiation site, we found that 11% (20) of patients who did not reach 
lower level facilities returned to RCWMCH for HIV care, and were generally less well when 
returning to RCWMCH compared to at the time of transfer. It is possible that these patients 
also experience a treatment interruption before returning to RCWMCH.[18]   
We observed favourable immunological and virological outcomes in children who transferred 
out successfully despite a relatively low proportion being virologically suppressed at transfer. 
This is likely because patients were on a trajectory of improving health at the time of transfer, 
and that this trajectory continued at the transfer site, rather than transfer causing an 
improvement in their health status. This also suggests good adherence in this group of children.  
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Both individual-level and structural-level factors have been identified as predictors of 
successful transfer for adults. An SA adult study showed that successful transfer was associated 
with living close to the transfer out site,[13] while a Kenyan adult study found a strong 
association between programme factors such as having an official transfer letter and successful 
transfer.[14] In our study, having a recorded transfer out site in the RCWMCH database was a 
strong predictor of successful transfer. It is possible that the record of a clinic site in the 
database indicates overall better documentation and management of the transfer process, such 
as contacting the referral clinic to make a specific booking for the patient. In addition, children 
transferred out from RCWMCH before 2010 are more likely to successfully transfer overall 
(i.e. have a laboratory test within 48 months of the transfer out date) compared to those 
transferred out after 2010. This is expected because children transferred out before 2010 had 
more time to re-engage with lower level facilities.22 
Recommendation and Conclusion 
A high proportion of children successfully transferred from RCWMCH with positive CD4 and 
viral load outcomes. These results indicate that decentralised paediatric HIV care is a feasible 
and promising strategy for improving both paediatric ART access and long-term retention in 
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